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Abstract
L’uso di particelle cariche pesanti in radioterapia prende il nome di adroterapia.
L’adroterapia permette l’irraggiamento di un volume bersaglio minimizzando il danno ai
tessuti sani circostanti rispetto alla radioterapia tradizionale a raggi X.
Le proprietà radiobiologiche degli ioni carbonio rappresentano un problema per i modelli
radiobiologici a causa della non linearità della loro efficacia biologica.
In questa tesi presenteremo gli algoritmi che possono essere usati per calcolare la dose
fisica e biologica per un piano di trattamento del CNAO (Centro Nazionale Adroterapia
Oncologica).
Un caso di particolare interesse è l’eventualità che un piano di trattamento venga in-
terrotto prima del dovuto. A causa della non linearità della sopravvivenza cellulare al
variare della quantità di dose ricevuta giornalmente, è necessario studiare gli effetti degli
irraggiamenti parziali utilizzando algoritmi che tengano conto delle tante variabili che
caratterizzano sia i fasci di ioni che i tessuti irraggiati.
Nell’ambito di questa tesi, appositi algoritmi in MATLAB sono stati sviluppati e im-
plementati per confrontare la dose biologica e fisica assorbita nei casi di trattamento
parziale.

Abstract
The use of heavy charged particles in radiotherapy is called hadron therapy.
Hadron therapy allows irradiation of target volume with much less damage to healthy
tissue compared to x-ray therapy.
The radiobiological properties of carbon ions represent a problem for radiobiological mod-
els due to the non linearity of the biological effectiveness of carbon ions.
In this thesis, we will present the algorithms that can be used to calculate physical and
biological dose for a given treatment plan at CNAO (National Center for Oncological
Hadron therapy).
A case of particular interest is the eventuality of a treatment plan being interrupted be-
fore the end of the daily irradiation. Dedicated algorithms have to be used to calculate
the actual biological dose delivered to the patient when parts of the the planned dose is
missed.
For this thesis, special MATLAB scripts have been developed and use to compare physical
and biological dose in the case of partial treatment.
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Introduction
The use of heavy charged particles – hadrons – for cancer radiotherapy purpose is called
hadron therapy.
Compared to conventional, X-ray based radiotherapy, this kind of treatment potentially
allows for a more efficient tumor irradiation, while reducing damage to healthy tissue.
This is due to a better spatial control on dose deposition, a characteristic of ions. During
the last 5 years, the number of hadron therapy dedicated centers quickly increased thanks
to good clinical results and subsequent interest by businesses.
Italian reasearch has contributed to the technological and scientific development of this
thecnology for the last 20 years and obtained three active hadron therapy centers within
the country. The first was born in Catania, at INFN’s Laboratori Nazionali del Sud,
where eye tumors have been treated since 2002 using ciclotron-accelerated proton beams.
The second – and first to be a dedicated hospital center – is CNAO, the National Centre
for Oncological Hadron therapy, situated in Pavia, which has been treating patients since
September 2011 using both protons and carbon ions. Finally, the proton therapy center
in Trento has been operating since 2014, and has been bought by Belgian Ion Beam Ap-
plications (IBA) company.
This thesis work has been conducted with CNAO and the Turin section of the INFN. The
main goal is to realize a suite of programs, in MATLAB, to easy compute and analyze
the delivered biological dose in case of interrupted treatment – i.e, if a part of the daily
irradiation session is missed. This situation, despite being rare, happens on occasion due
to machine related or patient related issues. When it happens, because of the non lin-
earity in the biological efficacy of carbon ions treatment, the actual delivered dose must
be recalculated, taking into account the reduced number of ions delivered and the partial
1
CONTENTS
target coverage.
To evaluate the dose delivered to a patient in a carbon ion treatment, an algorithm is
required to simulate the dose distribution taking into account the physical interactions
of particles with traversed tissues and subsequent biological effects.
In chapter 1 of this thesis we will see the physical and biological aspects of ionizing
radiation, we will approach the field called dosimetry and study the biological effects of
the radiation-matter interaction.
In chapter 2 we will introduce CNAO, where certain kinds of tumors are treated with
protons and carbon ions accelerated by a synchrotron. We will introduce the structure
and techniques used at CNAO.
In chapter 3 we will consider in more detail treatment plans used in hadron therapy, the
techniques employed and the radiobiology of carbon ions. The Local Effect Model, LEM,
will be introduced; it is the model used at CNAO that describes the radiobiological effects
of carbon ions.
In Chapter 4 we will learn Treatment Planning System, TPS, and in particular about
the TPS DEK (Dose Engine Kernel) used for this thesis. DEK is developed by INFN, in
particular at the Turin section in collaboration with the IBA, mentioned above.
Then we will consider the methods used to compare the biological dose distribution in
case of partial treatment introducing the Dose Volume Histogram, DVH.
Finally, in Chapter 5 we will analyze the plots that we obtained to evaluate the effects
of the relative biological effectiveness (RBE) in case of partial treatment for two patients
treated at CNAO.
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Chapter 1
Biological and physical aspects of
hadron therapy
Radiation therapy is the medical use of ionizing radiation to treat cancer. In conventional
radiation therapy, beams of X rays (high energy photons) are produced by accelerated
electrons and then delivered to the patient to destroy tumour cells. Using crossing beams
from many angles, radiation oncologists irradiate the tumour target while trying to spare
surrounding normal tissues. Inevitably some radiation dose is always deposited in the
healthy tissues.
When the irradiating beams are made of charged particles (protons and other ions, such
as carbon), radiation therapy is called hadron therapy. The strength of hadron ther-
apy lies in the unique physical and radiobiological properties of these particles; they can
penetrate the tissues with little diffusion and deposit maximum energy just before stop-
ping. This allows a precise definition of the specific region to be irradiated. The peaked
shape of the hadron energy deposition is called Bragg peak and has become the symbol of
hadron therapy. With the use of hadrons the tumour can be irradiated with less damage
to surrounding tissues than with X-rays.
The idea of using beams of high-energy charged particles in radiotherapy dates back to
1946 and is due to Robert R. Wilson, who first investigated the depth profile of the dose
achieved with proton beams, initially for shielding applications. Wilson was able to guess
the potential clinical benefits of this particular radiation, and predicted that an exact
small and well-defined portions of the body as target would soon be possible. Two years
later, at Lawrence Berkeley Laboratory in the USA, a sicrotrone was employed for pro-
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Figure 1.1: Proton (red-orange) and C-ion (green) centers active worldwide. The size
of the spot is proportional to the number of patients treated as indi- cated in the figure
legend
ton beams physical and radiobiological experiments. Initially, in 1954 the first patients
were treated with proton beams, then helium. From that moment, the use of protons
for therapeutic purposes and biological research has spread quite rapidly throughout the
world; because of complexity and cost of the accelerators to light ions, treatment by ion
beams was conducted initially using accelerators dedicated to fundamental research in
nuclear and particle physics. In 1993, the first hospital to become operationally dedicated
to hadrotherapy was the Loma Linda University Medical Center in California, currrently
about thirty proton centres are either in operation or in construction worldwide. Al-
though protons are used in several hospitals, the next step in radiation therapy is the use
of carbon ions. In Fig. 1.1 centres which are actually active worldwide are showed.
Conventional radiotherapy has two intrinsic drawbacks which arise from the shape of the
natural attenuation of the beam entering the body and its lateral diffusion. The attenu-
ation leads most of the overall dose being deposited before the target depth, while lateral
4
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diffusion limits the collimation of photon beams. These aspects make photon beams
scarcely apt to treat deep-seated tumors resulting in a substantial dose being delivered
to critical organs (Organs At Risk = OAR) in contrast to having just the required dose
deposited in the tumor. Hadron Therapy is ideally suited to treat tumors that are deep-
seated, located close to critical organs and which respond poorly to conventional photon
or electron radiotherapy. The clinical goal of a good radiotherapy technique is to maxi-
mize the damage to the tumor, and to minimize dose in the healthy tissues. Thanks to
their features, proton and carbon ion beams for therapy will not only improve the tumor
control probability for certain malignant diseases, but also reduce long-term complica-
tions in the surrounding healthy tissue. This "conformational therapy" is particularly
advantageous in the case of ocular, brain, salivary glands, backbone tumors and some
tumors at prostate and uterus. Well collimated protons beams and heavier ions permit
a conform irradiation of the target, following the contour with a millimetric precision
and sparing healthy tissue sourrounding the tumor in a better way than conventional
radiation. Treatment with protons permits to increase the prescribed dose to the tumor
without increasing exposition of vital organs. This largely increases the probability of
cure and optimizes the therapeutic outcome of critical organs. Although they have a bal-
listic accuracy, protons are not more efficient, in term of biological damage induced, than
photons or electrons in the treatment of radio-resistant tumors. Those tumors appear
to be more sensitive to beams which show an intense local ionization, as carbon, oxygen
or neon beams. These ions are said to have an high linear energy transfer (LET) and
are interesting in radiotherapy not only for their ballistic accuracy but also for their high
biologic effectiveness in comparison with γ radiation (RBE) and the reduced dependence
of the oxygen effect at cellular level (OER).
1.1 Biological effects of ionizing radiation
The term radiation defines the particular mode in which energy is propagated from one
point to another in space, in absence of macroscopic matter transport and without the
need of a substrate material support. Radiation can be divided into electromagnetic and
corpuscular: the former is constituted by electromagnetic fields oscillating with a certain
frequency (electromagnetic waves) which propagate in vacuum at speed of light, the
latter are constituted by particles of atomic or subatomic matter at high kinetic energy..
5
Chapter1. Biological and physical aspects of hadron therapy
Radiation is classified into ionizing and not ionizing based on its ability to ionize the
medium.
Ionizing radiation can be divided into two main categories:
• Directly ionizing: produces ions directly (particles α, β±)
• Indirectly ionizing: produces ions in an indirect way (X-rays, γ, neutrons)
1.1.1 DNA damage induced by ionizing radiation
Biological damage caused by radiations results from the ionization of
atoms forming the molecular structures of cells in living organisms.
A ionized atom will tend to produce new chemical bonds within the
molecule to which it belongs. The vital functions of the cell can be com-
promised if the damaged molecule is critical within the cell.
Deoxyribonucleic acid, DNA, is a nucleic acid that contains the genetic
information necessary to the biosynthesis of RNA and protein molecules
essential for the development and proper functioning of most living or-
ganisms. DNA is formed by four different nitrogenous bases: two purine
bases (Adenine and Guanine) and two pyrimidine bases (thymine and cy-
tosine) which, assembled in groups of three (triplets), are organized into
chains of nucleotides forming the various genes located on chromosomes.
Each gene provides for the coding of a particular protein. Each triplet
determines a well defined amino acid into the protein. Any errors occurring in response
to radiation can lead to position changes of the triplets in DNA molecules, resulting in
coding errors for protein building. Such changes can lead to diseases of genetic origin.
The radioinduced structural alteration of nucleic acids has a lethal effect on the cell when
the cell loses its ability to divide. This occurs because of an irreparable impairment
of hereditary information encoded in the nucleotide sequence of the DNA. It can occur
through three main mechanisms:
• Breaking of the main chain.
• Intramolecular bridges formation (covalent bonds, cross-link) that block the dupli-
cation process, preventing the separation of the two strands of nucleic acid.
6
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Figure 1.2: Principal DNA damage types induced by ionizing radiation.
• Structural modification of purine and pyrimidine bases. This can lead to a gene
mutation of greater or lesser gravity in function of the character-dependent gene
concerned.
Breaking of a single chain occurs when damage to one of the two chains leaves the
complementary strand intact. The repair mechanism of this kind of damage is quite
simple: the section of chain containing the breakage is removed and then rebuilt employing
the complementary chain as a reference and finally reconnected by an enzyme called ligase.
The number of broken individual strands has been shown to be linearly related to the
dose of radiation within a very wide range (from 0.2 to 60000 Gy), the average energy
required to produce a single break is comprised between 10 and 20 eV in the case of
weakly ionizing radiation.
Breaking of the double chain occurs when two breakages on individual adjacent chains
cause the detachment of part of the DNA. A double breakage can derive from a single
ionizing event due to the radiation itself, affecting two chains at once or to the combination
of two events due to different single breaking events which, incidentally, affect two nearby
points of two chains of the same macromolecule. The former happens especially with
highly ionizing radiation; in fact, the high density of delivered dose makes a double
breaking event quite probable. The latter occurs when the second radiaton damage is
dealt before the firse can be repaired. This most likely occurs in the presence of high dose
7
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rate. Has been experimentally sought the relationship between dose and number of double
breakage; the model more accepted is the linear-quadratic. It seems that a double chain
breaking can not be repaired or possibly can be repaired by an "error-prone" mechanism.
The dose dependence is linear-quadratic.
1.1.2 Cell survival curves
After a single dose of ionizing radiation, the number of living cells (surviving fraction)
decreases with increasing dose. The graphic expression of this phenomenon is the cell
survival curve.
The typical survival curve for mammalian cells
has a "shoulder" at low doses and becomes ex-
ponential only for higher doses. D0 determines
the slope of the linear part of the curve and
indicates the dose which reduces the surviving
fraction to a factor equal to 0.37. The number
of extrapolation N, wich is obtained by extrap-
olating the linear portion of the curve until it
intersects the y-axis, is an index of the cell’s
ability to store and repair the subletha dam-
age and represents the number of targets to hit.
Typically D0 has values between 1-2 Gy and N
between 1 and 5. The width of the shoulder is indicated by the parameter Dq (quasi-
threshold dose), which is the intersection between the extension of the exponential part,
straight part of the curve and the horizontal line passing through the 100% of survival.
To interpret the behavior of survival curves in which a shoulder is present, a theoretical
model has developed based on the assumption that inactivation of a cell requires the
inactivation inside the cell of a number n ≥ 1 of targets, each of which requires a single
shot to be inactivated (hypothesis of multiple targets single-shot). The inactivation of
the cell occurs only when a number of sublethal events occur within a short period of
time. At low dose, only a few events per cell will occur, thus making cell death unlikely..
There will be a dose range in which inactivation is not experienced (part of the shoulder).
8
1.1 Biological effects of ionizing radiation
At higher dose, interaction events within cells begin to add up, until the first inactivations
occur. The survival curve will begin to trend downward (passage between shoulder and
linear region). Increasing the dose again, the number of events per cell will keep growing,
trending to be n-1 in each of them. Above this dose, the behavior is identical to a system
of elements inactivable with a single blow, as a single additional event per cell will reach
the N threshold and cause inactivation.
The analytical expression corresponding to this theoretical model is the following:
f = 1− (1− e−
D
D0 )n (1.1)
This model implies a zero slope at low dose; however, experimental data is often not in
agreement with it. The suitable model for the majority of survival curves for mammalian
cells posits that cell death can be determined by a variety of processes. It then com-
bines the principles of the multiple targets model with a single event component. The
corresponding analytical expression is the following:
f = e
− D
D1
[
1− (1− e−
D
D2 )n
]
(1.2)
A model widely used in radiotherapy is the textbf linear quadratic. In this model, the
fraction of surviving cells is
f = e−(αD+βD
2) (1.3)
where D is the dose, α and β are two constants:
• α: log of cells killed per Gy, is the constant of proportionality linearly linking the
cellular lethality to single hit damage
• β: log of cells killed per Gy2, is the constant of proportionality quadratically linking
the cellular lethality to damage due to the sum of sub-lethal events
The ratio α/β is the dose in Gy at which lethality is equally likely to be due to single
events and to accumulation of sublethal damage.
According to this model there are two components that determine cell death by radiation:
a component proportional to the dose administered (α) and a component proportional
to the square of the dose (β). The component αD represents a non-repairable dam-
age (the dose / effect relationship is linear, from single shot, and therefore even small
9
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Figure 1.3: Fractionated irradiation: the overall dose is given by Df = Du + (n− 1)Dq,
where n is the number of fractionations.
doses are able to cause damage). The component βD2 indicates the existence of recov-
ery processes (more hit events), the dose should increase quadratically to surmount them.
In the case of fractionated irradiation, Fig. 1.3, at each subsequent irradiation reoccurs
the shoulder, because of a repair of sublethal damage by the elements of the system. The
overall dose, necessary to obtain the same degree of cell inactivation, must be increased
by ìDq times fractions -1.
The dose fractionation in radiation therapy involves a "therapeutic gain", in fact it in-
creases tolerance in normal tissues (due to repair and restocking phenomena) and at
the same time eliminates the radioprotective effects of hypoxia on tumor (due to re-
oxygenation phenomena).
1.1.3 Radiation quality
Although all ionizing radiations interact with living matter in a similar manner, different
types of radiation differ in their effectiveness, or ability to do harm to a biological system.
The various radiations, in fact, interact with matter in a different way in relation to the
amount of energy deposited along their path.
The transfer of energy of the radiation is defined by the LET (linear energy transfer)
10
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and denoted by the symbol L∆
L∆ =
(
dE
dl
)
∆
(1.4)
where dE is the local energy loss due to collisions for a charged particle along a track
segment dl, considering only collisions involving transfer of energy less than ∆ (in eV).
L∆ is habitually expressed in keV · µm−1. If ∆ =∞ all energy losses are considered.
High LET means high specific ionization. A particle can have a low LET at high energy
and a high LET at low energy.
• Low-LET radiations have tracks with primary
events (collisions) well separated in space, it is
the case of X-rays which are said to be sparsely
ionizing.
• High-LET radiations have tracks with primary
events not well separated in space, a dense col-
umn of ionization is produced. It is the case
of ions and heavy particles which are said to be
densely ionizing.
So a different LET leads, at equal doses, to different biological effects and to take account
of this fact the relative biological effectiveness, RBE, has been introduced. The intent is
to quantify the effect, at the same imparted dose, of a radiation r in comparison with a
reference radiation which is assumed to be that of X-rays at 250 kV. By this definition,
the reference radiation has RBE equal to 1. This way RBE, or weighting factors, quantify
the increment of biological effects of highly ionizing radiations with respect to X-rays at
the same physical dose.
Its follows: the RBE of some test radiation (r) compared with X-rays is defined by the
ratio
RBE =
D250
Dr
(1.5)
where D250 and Dr are respectively, the doses of X-rays of 250 kV, and the test radiation
required for equal biological effect. The higher the LET, the higher the biological effec-
tiveness (RBE), as it is shown in Fig. 1.4 for radiations of different LET.
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DRBE defined as the product of hadron absorbed dose, D, and hadron RBE
DRBE = D ×RBE (1.6)
is introduced to estimate the photon dose that would produce the same therapeutic effect
as the hadron absorbed dose, D, given under identical conditions.
An essential goal for the development of heavy ion therapy is not only to select with
the Bragg peak the tumor area, but also to maximize the difference in the biological
effectiveness between entrance channel and tumor area. The advantage of heavy ions
beams like carbon ions, in comparison with protons, is the higher relative biological
effectiveness at the beam range (about three times the RBE effectiveness at the end of
the range of the beam). At the entrance channel, the RBE is only slightly elevated. The
low dose in the entrance channel produces less and more reparable damage than the more
significant damage in the target volume. RBE is a function of radiation quality (LET)
(Fig. 1.4 ), radiation dose, fractionation, dose rate, cell tissue type, and end-point.
At last, because the presence or absence of molecular oxygen dramatically influences
the biologic effect of x-rays, has been introduced the oxygen enhancement ratio, OER,
defined as the ratio of doses under hypoxic to aerated conditions that produce the same
biological effect. Oxigen presence (aerated cells) increases radiation effectiveness for cell
killing, lack of oxygen (hypoxic cells) results in more radio resistant cells.
1.2 Radiation and dosimetric fields
When in a certain region of space radiations propagate (of any kind) it is said that this
region is the seat of a radiation field, described by field quantities. A simple way to
describe the radiation field consists counting the number of particles that pass through a
sphere of maximum section dA in a finite time interval. We define fluence of the radiation
field the number of particles dN crossing the ball during the experiment
Φ =
dN
dA
[
particle
cm
]
(1.7)
The fluence rate is the time derivative of the fluence:
φ =
dΦ
dt
[
particle
cm s
]
(1.8)
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Figure 1.4: The LET at wich the RBE reaches a peak is much the same (about 100
keV/µm) for a wide range of mammalian cells; as the LET increases, the RBE increases
slowly at first, and then more rapidly as the LET increases beyond 10 keV/µm, beyond
100 keV/µm, the RBE again falls to lower values. In the case of sparsely ionizing X-rays
the probability of a single track causing a DSB is low, thus X-rays have a low RBE. At
the other extreme, densely ionizing radiation (ex. LET of 200 keV/µm) readily produce
DSB, but energy is "wasted" because the ionizing events are too close together; thus,
RBE is lower than optimal LET radiation.
Figure 1.5: Variation oof OER and RBE as a function of LET of the radiation involved.
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Another important quantity is the stopping power, which is the rate (in terms of length)
with which a particle loses kinetic energy:
S = −dE
dx
[
MeV
cm
]
(1.9)
usually we use the massive stopping power, that is the proper stopping power depending
on the density of the material:
S
ρ
= − dE
ρdx
[
MeV
g/cm2
]
(1.10)
this quantity often loses its dependence on material crossed because dE/dx is divided by
the density ρ of the target.
The purpose of the dosimetry is to identify physical quantities to be put to quantitative
relationship with the effects (deterministic and stochastic) induced by ionizing radiation.
The oldest of the dosimetric quantities is the exposure and was introduced to describe
the ability of electromagnetic radiation to produce ionization in air
X =
dQ
dm
(1.11)
where dQ is the absolute value of the total charge of the ions, produced in the air when
all the electrons (positive and negative) released by the photons in the element of volume
of mass dm are completely stopped in the air. In SI exposure is measured in C kg−1. The
most commonly used, however, is the old special unit, the roentgen, R, whose value is:
1R = 2.58× 10−4CKg−1.
We define the absorbed dose
D =
dε̄
dm
(1.12)
as the mean energy imparted by ionizing radiation to a volume element of mass dm. For
purposes of radiation protection it is useful to define a mean absorbed dose to tissue or
organ, called organ dose
DT =
dεT
dm
(1.13)
Where εT is the total energy imparted in a tissue or organ and mT is the mass of that
tissue or organ. The unit of measurement is the Gray (1Gy = 1 J/Kg).
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L∞ (keV · µm−1) Q(L)
L<10 1
10 ≤ L ≤ 100 0.32L-2.2
L<100 300L−1/2
Table 1.1
The probability of stochastic effects depends not only on the absorbed dose, but also
on the type and energy of radiation. This fact is taken into account by weighing the
absorbed dose by a factor related to the quality of radiation. In the past this factor
has been applied to the absorbed dose at one certain point and called quality factor, Q,
related to LET radiation (table 1.1). The weight factor is now called weight factor of
radiation wR and depends on the type and energy of radiation. We call equivalent dose:
HT =
∑
R
wRDT,R (1.14)
where DT,R is the absorbed dose averaged over tissue or organ T, due to radiation R. The
value of the radiation weight factor is indicative of the relative biological effectiveness
value of that radiation to induce stochastic effects at low doses. The values of wR are
broadly compatible with the values of Q, related to the linear energy transfer (LET), a
measure of the ionization density along the track of a particle. The unit of measurement
is the Sievert, Sv.
The relationship between the probability of stochastic effects and the equivalent dose also
depends on the organ or the tissue irradiated. The equivalent dose in tissue or organ T
is then weighed with the tissue weight factor, wT , representing the contribution of that
organ or tissue to the total detriment resulting from uniform irradiation of the whole
body. Is then introduced the effective dose, as the sum of the weighted equivalent doses
in all the tissues and organs of the body:
E =
∑
T
wTHT (1.15)
where HT is the equivalent dose in tissue or organ T and wT is the weight factor for the
tissue T. The values of wT are chosen so that a equivalent uniform dose over the entire
body gives an effective dose numerically equal to the equivalent uniform dose. The sum
of the weight factors is therefore equal to 1 (see table 1.3.
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Type and energy range Weight factor
Photons of all energies 1
Electrons and muons of all energies 1
Neutrons, of energy < 10 keV 5
Neutrons, of energy from 10 keV to 100 keV 10
Neutrons, of energy from 100 keV to 2 MeV 20
Neutrons, of energy from 2 MeV to 20 MeV 10
Neutrons, of energy > 20 MeV 5
Alpha particles, fission fragments, heavy nuclei 20
Protons, of energy > 2 MeV 5
Table 1.2: All values are related to the incident radiation on body or, for inside sources,
emitted from the source.
1.3 Charged heavy particles interaction with matter
A charged particle passing through matter undergoes many collisions before being stopped.
To a first approximation we can assume that the slowdown occurs continuously (zig-zag
for electrons, straightforward for a heavy particle). The loss of energy is given by:
• Ionization and excitation of electrons in the medium.
• Molecular bonds breakage (radical formation).
• Radiation emission.
According to classical electrodynamics, a charged particle subjected to an acceleration
a emits radiation proportional to a2. For a particle that passes near a nucleus, a ∝
Z/M where Z is the atomic number of the nucleus and M the mass of the particle, the
emitted radiation is proportional. to (Z/M)2. Due to the term
(
1
M
)2, the radiative loss
is significant only for electrons.
The mode of interaction of charged particles depends on the energy of the particles and
the minimum distance they reach from the nucleus.
• Distant collisions: the atom is excited or ionized.
• Nearby collisions: peripheral electrons extraction and energy loss.
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Organ or tissue Weight factor
Gonads 0.20
Red bone marrow 0.12
Colon 0.12
Lung 0.12
Stomach 0.12
Bladder 0.05
Breasts 0.05
Liver 0.05
Esophagus 0.05
Thyroid 0.05
Skin 0.01
Bone surface 0.01
Remaining organs and tissues 0.05
Table 1.3: These values were derived from a reference population, comprising an equal
number of individuals of both sexes and a wide range of ages. These values apply to
workers, to population and to both sexes.
1.3.1 Bethe-Block formula
When a heavy charged particle passes through a material, the average loss of energy
per unit path length is given by the following theoretical expression ( Bethe-Bloch
formula):
−dE
dx
=
4πe4z2ZNB
mv2
(1.16)
with
B = ln
[
2mv2
I(1−β2)
]
− β2
where z is the charge of the particle, Z the atomic number of the medium, N is the number
of atoms per cm3 of the absorbing material, M is the mass of the electron, I the average
potential of ionizationl of the absorbent substance atoms and β = v/c.
The formula of Bethe-Bloch is independent of the mass of the particle and is valid as long
as the energy of the incident particle is much higher than the ionization potential of the
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Figure 1.6: Energy loss as function of the particle energy.
electrons.
The trend of the energy as a function of energy loss (dE/dx) depends strongly on the
energy of the particle. As you see in Fig. 1.6, at low energy the term 1/β2 dominates,
reaching a minimum ionization point and for higher energies there is a relativistic lift.
For very low energies, when the speed of the primary particle becomes of the same order
of magnitude as the velocity of the electron orbital, the formula is no longer valid.
1.3.2 Bragg curve
The increase in ionization near the end of the path is explained by the dependence of the
stopping power by the term 1
v2
in the formula 1.16. The specific ionization remains almost
constant until near the checkpoint of the particle, where it rapidly increases, giving rise
to the so-called Bragg peak.
The stopping power is an additive quantity, therefore, for a material that is a mixture
of elements, it can be rewritten as:
S
ρ
=
∑
wi
(
S
ρ
)
i
(1.17)
See Fig. 1.8 to understand the use of Bragg peak to achieve the tumor depth with respect
conventional radiotherapy.
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Figure 1.7: The Bragg curve of 5.49 MeV alphas in air has its peak to the right and is
skewed to the left.
Figure 1.8: Use of Bragg peak in hadron theraphy.
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Figure 1.9: Dispersion across the track, Rm is the average range, Re the extrapolated
range.
1.3.3 Energy and range straggling
The heavy charged particles lose energy in collisions with continuity and, mainly because
they interact with atomic electrons, are slightly deflected from their trajectory while
maintaining a nearly straight path until they stop. This behavior explains the trend of
attenuation curve.
Each particle has a trajectory of its own and all the particles having the same initial
energy have a path that differs statistically from each other.
Average range: Absorber thickness which reduces to 50% the number of particles α
transmitted.
Extrapolated range: It is obtained by extrapolating to zero the linear portion of
the transmission curve.
The difference, δ, between middle path and extrapolated path is called straggling. For α
of 5 MeV it is ∼ 1%.
The range of the charged particles can be expressed as:
Rcalc =
∫ Lf
0
dx =
∫ 0
Ei
1
(dE/dx)
dE (1.18)
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In first approximation, neglecting the variation of B with v, you have there the average
path of a charged particle of mass M and charge ze (from energy E0 to 0) is given by:
Rz,M =
∫ 0
E0
dE
dE
dx
=
∫ E0
0
Mmv2AdE
M4πe4z2ZρN0B
≈ mA
2πe4z2ZρN0BM
∫ E0
0
EdE =
mAE20
4πe4z2ρMZN0B
(1.19)
A, ρ and Z are material properties; in two different materials, for particles of a certain
type and of a given energy, you have:
R1
R2
=
Z2ρ2A1
Z1ρ1A2
≈ ρ2
ρ1
(
⇒ Z2
A2
≈ Z1
A1
)
(1.20)
When it is known the relationship between the energy and the penetration depth for a
certain particle type and for a given material, one can determine the corresponding rela-
tionship for a different type of particle in the same material. Considering the dependence
of B on the speed v, instead of 1.19 you get:
Rz,M(E0) =
∫ 0
E0
dE
dE
dx
=
Mm
4πe4z2ZN
∫ v
0
v3dv
B(v)
(1.21)
dove si è usata where is used the relation E = 1
2
Mv2 RightarrowdE = d
(
1
2
Mv2
)
=
Mvdv. You can then rewrite:
Rz,M(v) =
M
z2
F (v) (1.22)
where F(v) is essentially the integral 1.21, evaluated between the limits 0 and v. The
equation 1.22 shows that for different types of fast particles in an absorbent material, the
penetration depth depends only on the velocity of the particle, from its mass M and the
charge z.
Using the 1.22 we can relate Rp(v), depth of penetration of a proton with speed v, with
the depth of penetration of a particle of mass M and charge z, equipped with the same
speed:
Rz,M(v) =
Mz2pRp(v)
mpz2
⇒ Rz,M(v) =
MRp(v)
z2
(1.23)
At constant speed the energies, in the non-relativistic case , are linked by the relation:
Ep =
1
2
mpv
2
EM =
1
2
Mv2
⇒ Ep =
mp
M
EM ⇒ Ep =
EM
M
(1.24)
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Figure 1.10: Measured Bragg peaks of protons and 12C ions having the same mean
range in water Schardt et al.,2008
and then
Rz,M(E) =
MRp(E/M)
z2
(1.25)
Known the range of a proton in a given material, it’s possible calculate the range for
different mass particles, having the same speed.
In typical biological tissue, range straggling amounts to about 1% of the mean range for
protons and only to 0.3% for carbon ions (Fig. 1.10).
The variance σ2R of the range straggling is related to the variance σ2E of the energy-loss
straggling by:
σ2R =
∫ Ei
0
(
dσE
dx
)(
dE
dx
)−3
dE (1.26)
The ratio of the straggling width σ2R and the mean range R is nearly constant and can
be described by:
σ2R
R
=
1√
m
f
(
E
mc2
)
(1.27)
where f is a slowly varying function depending on the absorber and E and m are the
particle energy and mass.
In practice, the profile of the Bragg peaks is broader, mainly due to the density inho-
mogeneities of the penetrated tissue. Furthermore, for scanning beam delivery systems
using slice-by-slice irradiation of the target volume, it can be even advantageous to widen
the sharp Bragg peaks by passive systems in order to reduce the treatment time.
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Figure 1.11: Plot of energy distribution of a beam of initially monoenergetic charged
particles at various penetration distances. E is the particle energy and X is the distance
along the track. Over the first portion, the distribution becomes wider (and more skewed)
with penetration distance, showing the increasing importance of energy straggling. Near
the end of the range distribution narrows again because the mean particle energy has
greatly been reduced.
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1.4 Nuclear reactions
Unlike e+, − and γ, heavy particles can interact with matter also via strong nuclear force.
Different nuclear process dominate at different energies: interaction mechanisms vary
from transfer reactions, observed at low energies, to fragmentation processes, observed at
the highest energies around 1 GeV/u. In therapeutic applications peripheral collisions,
in which fragments are stripped of only few nucleons, are the most frequent reactions,
especially in the first few centimeters of depth. Because of the reaction kinematics,
projectile fragments travel nearly in forward direction at almost the same velocity as
the incident particle and may therefore cause further fragmentation reactions, while the
target nuclei remain approximately at rest. The secondary fragments, due to have lower
charge, and the same velocity of the projectile, have a longer range than the primary beam
particles, giving rise to an undesirable dose deposition beyond the Bragg peak. Dose tails
are problematic, because they affect healthy tissues beyond the tumoral volume. The
ratio between deposited dose at peak and at tail depends on the particle, primary or
secondary, mass. For Lithium and Carbon ions this crucial ratio is of the order of 15%,
for Neon ions it is about 30%. The fragments associated must be summed to the one
from primary beam at the energy of treatment planning, and finally must be multiplied
by the RBE of the various nuclear species generated.
For protons beam, only target fragmentation is possible; although EM interactions of
protons dominate, nuclear interactions are not quite rare enough to be neglected. They
are more difficult to model but they can be taken into account well enough by using
experimentally measured Bragg Peaks. However, their biological effect turns out to be
small. According to ICRU63 definitions they are divided in:
• Elastic, which are reactions where the incident particle scatter off the target nucleus
conserving total kinetics energy. The internal state of both target nucleus and the
projectile does not change.
p+16 O −→ p+16 O (1.28)
• Inelastic, which are a subcategory of the nonelastic reactions because the kinetic
energy is not conserved but the final nucleus is the same as the bombarded nucleus.
p+16 O −→ p+16 O∗ (1.29)
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• Nonelastic, which are nuclear reactions that are not elastic, so the kinetic energy
is not conserved, and the target nucleus may breakup, or be excited into an higher
quantum state... etc.
p+16 O −→ p+ p+15 N (1.30)
p d t He-3 α Recoils n γ
0.57 0.016 0.002 0.002 0.029 0.016 0.20 0.16
Table 1.4: Percentage of secondaries produced by 150 MeV protons with 16O.
Protons that slow down and stop in matter are called primaries, instead particles from
inelastic and nonelastic nuclear reactions are called secondaries. Possible secondaries
from nonelastic reactions at therapy energies are protons, neutrons, gamma rays, heavy
fragments and recoiling residual nuclei. The importance of each is the fraction of the
initial energy carried away. Table 1.4 shows relative energy fraction for 150 MeV protons
impacting on 16O nuclei. Total energy imparted to charged particles is 0.64 MeV, and
alphas take away only 2.9% of total energy. The RBE enhancement comes from the
abundant secondary and, at the distal end of the Bragg Peak, primary low-energy protons.
Thanks to the fact that secondaries typically make large angles with the beam axis,
unlike primaries which despite multiple scattering rarely exceed a few degrees, secondaries
produced in scatterers or absorbers will clear out of the beam before they reach the
patient.
For heavier ions, fragmentation is the most important process leading to the build-up of
the secondary particles along the penetration depth. Some important conclusions can be
drawn on the effects of fragmentation relevant to high-energy ion beam radiotherapy:
• Nuclear reactions cause a loss of primary beam particles and a buildup of lower-Z
fragments. These effects become more and more important with increasing pene-
tration depth, or initial beam energy.
• Secondary (or higher-order) projectile-like fragments move with about the same
velocity as the primary ions. They have in general longer ranges and produce a
dose tail behind the Bragg peak.
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Figure 1.12: Buildup of secondary fragments produced by 400 MeV/ u C-12 ions stop-
ping in water.
• The angular distribution of fragments is mainly determined by reaction kinematics
and forward directed, but is much broader than the lateral spread of the primary
ions caused by multiple Coulomb Scattering.
See Fig. 1.12 to have an idea of the build up of secondary fragments produced by 400
MeV/u 12 C ions stopping in water.
The impact of nuclear fragmentation on depth dose profile is shown in Fig. 1.13. As
already mentioned, with increasing penetration depth the peak-to-entrance dose ratio
becomes gradually smaller, mainly due to the exponentially diminishing flux of primary
ions. The buildup of lower-Z fragments is clearly visible in the dose tail behind the Bragg
peak at larger depths. Additionally, Bragg peaks are increasingly broadened by straggling.
In comparison to 12C ions these effects are much more pronounced in the example shown
in Fig. 1.14 for 670 MeV/u 20Ne ions with a range of about 36 cm in water. The
peak-to-entrance dose ratio is only 1.5 in this case. The calculated contributions of the
primary ions and second and third generation fragments are based on a semi-empirical
fragmentation cross-section formula (Sihver et al., 1998).
Clinical applications require a relatively uniform release of the dose at target volume.
Therefore the beam must be spread out laterally and along the depth. This is obtained
by overlapping different Bragg peaks of specific intensities and energies, both with the
active and passive technique, and the resulting dose distribution is called Spread-Out-
Bragg-Peak (SOBP), see Fig. 1.16. The SOBP amplitude is defined as the distance
between the dose level at 90% proximal and the 90% distal on the depth-dose curve. In
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Figure 1.13: Measured Bragg curves of 12C ions stopping in water.
Figure 1.14: Bragg curve for 670 MeV/u Ne-20 ions in water at GSI (circles) and
calculated contributions of primary ions, secondary and tertiary fragments.
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Figure 1.15: Schematic representation of the variation with depth of RBE, showing the
profile of the (physical) dose required to obtain a flat SOBP in term of "biological dose".
order to obtain a uniform release of the dose at target volume the rise of RBE over the
SOBP must be considered, clearly related to the presence at the end of the range of low-
energy, thus high-LET, particles. In general, at the "entrance channel" of a hadron beam
the high-LET component is small. Here, for example, protons behaves much like a photon
beam and the subsequent LET rise is quite limited so that only over the last millimeters
or fractions of millimeters the low-energy, high-LET, component is large enough to give
an RBE significantly larger than 1. For carbon ions there is a significant increase in RBE
over all the SOBP. If an homogeneous biological effect is desired over the tumor volume,
then the physical dose of the carbon beam has to decrease towards the distal edge (Fig.
1.15). The ratio between RBE around the Bragg peak and that in the entrance plateau
region is a significant factor determining how much the traversed tissue can be spared.
The proportion of low-energy, high-LET, particles varies with depth and strongly depends
on the beam initial energy, as it can be seen from the example shown in Fig. 1.13. For
protons with 200-250 MeV initial energy only over the last millimeters, or fraction of
a millimeter, this component is significant, giving an RBE significantly larger than 1.
Slightly larger variation, though still of limited amount, along the SOBP are expected for
protons beams with lower initial energy, such as those used for ocular treatment (typically
around 60 MeV). Therefore, in an extended Bragg maximum the RBE critically depends
on the local compositions of the beam energy, atomic number and intensity. This is
illustrated in Fig. 1.16 where extended Bragg curves of different physical dose shapes
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Figure 1.16: In a typical treatment plan for proton therapy, the Spread Out Bragg
Peak (SOBP, dashed blue line), is the therapeutic radiation distribution. The SOBP is
the sum of several individual Bragg peaks (thin blue lines) at staggered depths. The
depth-dose plot of an X-ray beam (red line) is provided for comparison. The pink area
represents the additional dose delivered by X-ray radiotherapy which can cause damage
to normal tissue and secondary cancers, especially of the skin.
are used to determine survival and RBE with the goal was to achieve a flat top of cells
survival over the target volume.
29

Chapter 2
The status of CNAO
The CNAO (Italian acronym that stands for National Centre for Oncological Hadron
therapy) is situated in Pavia, Italy. It is a clinical facility created and financed by the
Italian Ministry of Health and conceived to supply hadron therapy treatments to patients
from all over the Country. A qualified network of clinical and research institutes, the
CNAO Collaboration, has been created to build and run the centre. This organizational
model turned out to be very efficient and fruitful to reach the goal of introducing the
most advanced techniques and procedures of hadron therapy. Three treatment rooms with
four beam ports (three horizontal and one vertical) are operational and one experimental
room has been built. Beams of protons with kinetic energies up to 250 MeV and beams
of carbon ions with maximum kinetic energy of 400 MeV/u are transported and delivered
by active scanning systems. This operation started in 2009 with the commissioning of
the high-technology components that form the acceleration chain from the sources to the
patient. The dosimetry and radiobiology tests have been completed with proton beams
and CNAO obtained the authorisation to start treating patients. Statistics from the
Italian Association of Radiotherapists and Oncologists (AIRO) have estimated that more
than 3% of the overall Italian radiotherapy annual patients, i.e. more than 3000 new
patients per year, would preferably be treated with hadron therapy, but this number is
steadily increasing. Pre-selection criteria are defined on the basis of established clinical
protocols, and hospitals and clinics in the network adress to CNAO those patients that
satisfy the criteria. This paper outlines the project development, the technical aspects of
the realisation and commissioning and the clinical issues that are relevant for treatments
at CNAO.
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Figure 2.1: The CNAO hospital building in Pavia.
2.1 CNAO facility
The construction of CNAO facility was completed at the beginning of 2010 in Pavia. The
centre is placed in an area that hosts other hospitals and the university campus, thus
allowing the creation of synergies and collaborations. The entrance is shown in fig. 2.1.
The large usage of windows allows to bring daylight to most of the areas, an architectural
solution to improve the quality of life of operators and patients. The cross section in Fig.
2.2 shows the central cavedium reaching the underground waiting area, the structure of
the centre on four levels and the clear distinction between hospital and technical areas.
Inside the building the following functional areas are present [23]:
• The outpatient service.
• The imaging service (diagnostics in images and nuclear medicine).
• The therapeutic service (hadron therapy).
• The administrative departments and the offices of personnel.
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Figure 2.2: Cross-section of the CNAO.
• General services, such as the bar, the conference hall, meeting rooms, and the
reading room.
• Technological areas, including electrical power plants, thermomechanical and spe-
cial plants that provide energy for the building, the central electricity transforma-
tion units and the technical areas at the service of high technology.
The space organization envisages the merging of the functions of high users flow on the
groundfloor and the basement; all health services are located here. This choice is justified,
in the first case, by the immediate accessibility from outside and, secondly, by the need
to ensure an appropriate radiation shielding for the rooms used for tumour treatment.
Personnel offices, conference and meeting rooms and other service areas are located on
the first and second floors. Every day, the medical personnel works on the treatments
of clinical trials included in the experimental programme. During the routine operation
phase, the medical team counts about 80 people. The Accelerators Department has been
completed, and the machine is running 7 days per week, 24 hours a day. During the shifts
two persons are continuously present in the main control room.
2.2 CNAO accelerators and beam lines
The main accelerator at CNAO is a synchrotron, a circular accelerator of about 25 m in
diameter. The sources, the lines of injection and the linear accelerator are housed inside
the ring. Outside the main ring there are four extraction lines, about 50 m each, leading
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Figure 2.3: View of the CNAO accelerators.
the extracted beam into three treatment rooms. Each of the two side rooms receives a
horizontal beam, while the central hall receives both a horizontal and a vertical beam.
A view of the complex of accelerators and lines is shown in Fig. 9. CNAO is designed
to work with ions with 1 ≤ Z ≤ 6 and possibly with oxygen ions, although with reduced
penetration. In water, the beam is able to achieve depths between 3 and 27 gcm−2 and
its intensity is such to administer 2 Gy for a volume of 1 l in about 1 minute. The dose
is delivered to the tumour with an active scanning system with a uniformity of ±2.5%.
The main physical parameters of the beam are reported in table 4. The availability of
the machine must be close to 100% in the time reserved for medical use because therapy
cannot be interrupted for long periods. The following part of this section is a description
of the most meaningful and complex systems of the lines and accelerators.
2.2.1 From sources to injection in the synchrotron ring
At CNAO two identical-sources of type ECR (Electron Cyclotron Resonance) are operat-
ing. Each source can produce several kinds of beams simply by changing the gas used to
produce plasma and optimizing the settings of certain parameters, such as the RF power
and the potential of extraction electrodes.
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This way, each source is able to compensate for the possible absence of the other. In nor-
mal operation conditions, each source produces only one type of beam, protons or carbon
ions, which allows to change quickly the type of accelerated ion. The beam undergoes
the following acceleration steps:
• The two ECR (Electron Cyclotron Resonance) sources run continuously and the
particle type to be accelerated is selected by changing the LEBT (Low Energy
Beam Transfer) magnet settings.
• The LEBT is the line that transports the beam from the sources to the radiofre-
quency quadrupole (RFQ). The kinetic energy of the beam in LEBT is 8 keV/u,
which corresponds to the RFQ injection energy.
• The RFQ has an output energy from of 400 keV/u and provides a suitable beam to
be accelerated by the LINAC.
• Then the LINAC accelerates the beam of 400 keV/u to 7 MeV/u in one 3.8 m
long tank. It is composed of four accelerating sections among which three triplets
of quadrupoles for beam focusing are housed. Immediately after the tank of the
LINAC, there is a fourth triplet which focuses the beam onto the stripping foil.
Bunches of C 6+ or protons are completely produced by this latter.
• The MEBT transports the beam from the stripping foil to the synchrotron.
• The synchrotron has a diameter of about 25 m. Protons and carbons are injected
at 7 MeV/u and accelerated to energies between 60 MeV and 230 MeV for protons
and between 120 MeV/u and 400 MeV/u for carbon ions. In the synchrotron there
are 16 dipoles and 24 quadrupoles. The beam acceleration is provided by a single
RF cavity which acts in four phases:
– beam adiabatic capture
– acceleration
– preparation of the beam for extraction
– stabilization of the extracted beam
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Figure 2.4: Principle of active dose distribution.
Capture and acceleration occur by tuning the cavity to the revolution frequency of
the beam (using a harmonic number h = 1) and synchronizing it with the energy
increase and the magnetic field value. At the end of the acceleration, the beam
must be prepared for extraction.
• The HEBT (High Energy Beam Transfer) transports the extracted beam to the
three treatment rooms through four lines, one of these treatment rooms having
both a horizontal and a vertical line. HEBT is equipped with a system, called
chopper, to dump the beam when necessary.
2.2.2 The dose delivery system
CNAO is designed for a fully active dose distribution system. This means that the tumour
is ideally divided into "slices", i.e. into regions that are reached by particles of the same
energy. Each slice is then irradiated by "painting" it with a pencil beam, somehow as it
happens ona a TV screen for the reconstruction of the image. The concept is illustrated
in fig. 2.4. This way, the beam is directed to the various points of the tumour by varying
its position without adding additional thicknesses on the path of the beam that can lower
its quality.
Energy is varied by the synchrotron to choose the slice, and the beam moves within
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Figure 2.5: Schematization of the CNAO monitoring system placed upstream the pa-
tient.
the slice thanks to the finely laminated scanning magnets. The maximum speed with
which the beam can be moved by the scanning magnets is 20 m/s. The position of the
beam is controlled in real time thanks to a system of monitors that measure the beam
position and the number of particles received by each voxel. This system (illustrated in
fig. 2.5) is used both to decide when the foreseen dose for each voxel has been reached
and to correct the position of the beam by acting on the scanning magnets. There are
two identical measurement systems and each of the two detectors (Box1 and Box2) in
sequence measures and controls separately the beam parameters: position, profile and
number of particles. Discrepancies in the measurements lead to fast beam interruption by
acting on the chopper magnets in very short times. Finally, it is worth mentioning that
all along the beam path there are sensors that measure and control the characteristics
of the particle beams. Moreover, the entire complex is managed by a complex control
system that was designed to automatically guide irradiaton of the patient and avoid all
human actions, which are sources of potential errors and inaccuracies.
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Chapter 3
Hadron therapy treatment planning
Radiation treatment planning is the process of planning the appropriate treatment of
external beam radiotherapy or internal brachytherapy for a cancer patient. The medical
team consists of radiation oncologists, radiation therapists, medical physicists and medi-
cal dosimetrists.
Typically, medical imaging (i.e., X-ray computed tomography often the primary image set
for treatment planning, magnetic resonance imaging excellent secondary image set for soft
tissue contouring, and positron emission tomography less commonly used and reserved
for cases where specific uptake studies can enhance planning target volume delineation)
is used to create a virtual patient for a computer-aided design procedure. Treatment
simulations are used to plan the geometric, radiological, and dosimetric aspects of the
therapy using radiation transport simulations and optimization. For intensity modulated
radiation therapy (IMRT), this process involves selecting the appropriate beam (photons,
and perhaps protons), energy (e.g. 6 MV, 18 MV) and arrangements. The more formal
optimization processes are typically referred to as forward planning and inverse planning
[7] [11]. Plans are often assessed with the aid of dose-volume histograms (DVH), allowing
the clinician to evaluate the uniformity of the dose to the diseased tissue (tumor) while
sparing healthy structures.
Today, treatment planning is almost entirely computer based, using patient computed
tomography (CT) data sets. Modern treatment planning systems provide tools for mul-
timodality image matching, also known as image coregistration or fusion.
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3.1 Ion therapy development
3.1.1 Forward and inverse planning
Forward planning is a technique used in external-beam radiotherapy to produce a
treatment plan. In forward planning,a dosimetrist organizes beams into a radiotherapy
treatment planning system which can deliver sufficient radiation to a tumour while both
sparing critical organs and minimising the dose to healthy tissue. The required decisions
include how many radiation beams will be used, which angle each beam will be delivered
from, whether to use attenuating wedges, and which multileaf collimator configuration
will be used to shape the radiation from each beam. Once the treatment planner has
made an initial plan, the treatment planning system calculates the required monitor
units to deliver a prescribed dose to a specific area in the patient which depends on beam
modifiers that include wedges, specialized collimation, field sizes, tumor depth, etc. The
information from a prior CT scan of the patient allows more accurate modeling of the
radiation behaviour as it travels through the patient’s tissues. Different dose prediction
models are available, including pencil beam, convolution-superposition and monte carlo
simulation, with precision versus computation time being the relevant trade-off. This
type of planning is used for the majority of external-beam radiotherapy treatments, but
it is only sufficient to handle relatively simple cases-cases in which the tumour has a
simple shape and is not near any critical organs. For more sophisticated plans, inverse
planning is used to create an intensity-modulated treatment plan. This is now also used
as a part of post-mastectomy radiotherapy (PMRT) planning.
Inverse planning is a technique used to design a radiotherapy treatment plan. A
radiation oncologist defines a patient’s critical organs and tumor, while a dosimetrist
gives target doses and importance factors for each. Then an optimisation program is
run to find the treatment plan which best matches all the input criteria. In contrast to
the manual trial-and-error process known in oncology as "forward planning", "inverse
planning" uses the optimiser to solve the Inverse Problem as set up by the dosimetrist.
Outside of the oncology field, this procedure might be described as "automated planning".
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Figure 3.1: Graphic representation of forward (a) and inverse (b) planning.
3.1.2 Intensity Modulated Proton Therapy
The origins of the term Intensity-Modulated Radiotherapy (IMRT) are rather obscure, but
there is no doubt that this technique has revolutionized radiotherapy practice [2]. How-
ever, the term is rather misleading; for most protons, IMRT delivery systems actually
modulate fluence (i.e. the total number of particles delivered per unit of area) by varying
the dwell time of the beam at a location, rather than directly modulating intensity (the
number of particles delivered per unit of area per unit of time). More importantly, how-
ever, the success of IMRT lies not in the process of modulation itself, but in the ability of
the IMRT treatment planning and delivery system to deliver arbitrarily complex fluence
patterns from each field. Therefore, IMRT as a delivery method was only realized after
the inclusion into the planning process of algorithms to calculate the fluence patterns
and the development of devices such as dynamic multileaf collimators that allow fluence
patterns to be delivered.
Pencil beam scanning for ions is a dynamic delivery technique that relies on the modula-
tion of energy and fluence, by varying the dwell time of the beam or by varying the beam
intensity, and on an optimization algorithm in the treatment planning process by which
fluences and energies can be calculated. IMRT only achieves fluence modulation on the
plane which is orthogonal to the beam direction; IMRT is therefore a "two-dimensional"
optimization problem where, given the treatment plan constraints, the fluence at a point
in that plain is optimized. IMPT, in contrast, has an additional degree of freedom pro-
vided by the beam energy, which allows the pristine Bragg peak to be positioned along
the beam direction. Therefore, an IMPT field modulates the fluence and position of
each pristine Bragg peak, and achieves "three dimensional" optimization within a target
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volume. A single IMPT field can therefore achieve full dose conformation to the target,
albeit perhaps not optimal compared to the use of multiple fields.
There are two distinct techniques to calculate pencil beam scanned plans. The first is
defined as Single Field, Uniform Dose (SFUD) planning. In this approach, the fluences
are calculated and optimized individually for each field of a plan, with the sole constraint
of achieving a homogeneous dose across the whole target volume from each individual
field. The second technique is IMPT.
Altough it is always difficult to completely distinguish one delivery method from the
others, the term intensity-modulated proton therapy was first coined by Lomax in 1999.
Using the analogy with photon IMRT, it is defined in that paper as a method where
"... a number of individually inhomogeneous (in dose) fields are calculated in such a way
that, when combined, these fields deliver a homogeneous and conformal dose to the target
volume while simultaneously reducing dose to selected normal tissue types."
The key here is the definition of inhomogeneous fields that differentiates this delivery
technique from SFUD pencil beam scanning. In practice, the major operational differ-
ence between the two techniques lies in the optimization process, with all Bragg peaks of
all fields of an IMPT treatment being simultaneously optimized with common constraints
to the targets and surrounding critical organs. The result is a set of (sometimes highly)
inhomogeneous dose distributions, which provides the desired target coverage only when
all fields are combined (thus, the case of partial treatment becomes problematic).
Perhaps the best way to illustrate the rather subtle difference between SFUD and IMPT
treatments is with an example. Consider the dose distributions shown in Fig. 3.2 [2].
From left to right are shown dose distributions calculated to the same pelvic Ewing’s
sarcoma using passive scattering, pencil beam scanning using the SFUD approach and
IMPT. The bottom row shows three-field plans calculated using the same field directions
for the three different delivery modes, while the top row shows the anterior field of each
plan alone.
The dose distribution for the anterior field for passie scattering does not appear to be very
conformal (Fig. 3.2 top-left panel). Altough we have a very homogeneous dose across
the planning target volume (PTV) (the yellow contour), and a sharp dose falloff at the
distal and lateral aspects of the PTV, it is clear that the high dose (>90%) region covers
most of the normal tissues in the proximal path of the beam. As the range modulation is
performed before the scattering foils, it is impossible to vary the extent (in depth) of the
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Figure 3.2: Three-field plans for passive scattering, SFUD and IMPT. The top row
shows the anterior field of each plan, while the bottom row shows the combined distribu-
tion for all three fields. Dose levels are from 90% (red) through to 30% (blue) [2].
SOBP across th field. Therefore, in order to ensure a homogeneous coverage of the PTV,
the extent of the SOBP must be the same as the longest extent of the PTV along the
beam direction. When the extent of SOBP is applied to narrower portions of the target,
the high dose region extends well beyond the proximal portion of the PTV, and even
back the patient’s surface. Only when multiple beams are applied is the conformation
to the target improved, with some sparing of the femoral head then being achieved (3.2,
bottom-left panel).
Figure 3.2 shows the equivalent field and plan for an SFUD pencil beam scanning treat-
ment. Altough not strictly correct, it is peraphs convenient for this discussion to consider
the SFUD technique to be a method by which variable extent SOBP pencil beams can be
applied across the PTV. That is, where the extent of the PTV is narrow, a narrow SOBP
can be delivered, where it is broad, a correspondingly broader SOBP can be delivered.
The SOBP is therefore tailored exactly to the extent of the PTV along each ray at the
proximal and distal extents. The excessive dose delivered to the proximal tissues as a re-
sult of the use of a fixed extent SOBP is therefore reduced. The result is a 3-D conformal
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dose, which, when considering the full plan, lead to considerablyimproved sparing of the
femoral head and a significantly reduced integral dose to all surrounding normal tissues
(compare the 30% isodose in the bottom, left and middle panels of Fig. 3.2.
Now consider the IMPT results in Fig. 3.2, which shows the equivalent anterior field and
three field plans. As with SFUD planning, IMPT requires an optimization procedure
to determine the weights of all the Bragg peaks delivered from each peak, with the ma-
jor diference to SFUD planning being that the Bragg peaks from all field are optimized
simultaneously. The result is that each indvidual field delivers a very inhomogeneous
dose distribution, as indicated in the top-right panel of Fig. 3.2. When we combine the
anterior field with the other two fields, with similarly inhomogeneous dose distributions
(not shown), we obtain the three field dose distribution shown in the lower-right image of
figure 3.2. A highly conformal and homogeneous dose is still delivered to the PTV, but
with near total sparing of the femoral head. In contrast to the differencebetween passive
scattering and SFUD delivery, however, the difference in integral dose going from SFUD
to IMPT treatments is negligible, in that the low-to-mid level doses have been simply
redistribuited in comparison to the distribution of the SFUD plan (bottom-middle panel
of Fig. 3.2).
In summary, the potential advantages of pencil beam scanning, using SFUD or IMPT,
over passive scattering are twofold. First, the use of scanning allows for an efficient de-
livery of the high dose to the target volume, thereby reducing integral dose to all normal
tissues. Second, the simultaneous optimization of fields allows to deliver highly inhomo-
geneous, but optimized, single fields, which in turn give more flexibility in where exactly
the residual dose is delivered to normal tissues.
3.1.3 Spot scanning
In scanning beam techniques, magnets deflect and steer the proton beam. Under com-
puter control, the beam "paints" the treatment volume, voxel by voxel, in successive
layers. The depth of penetration of the Bragg peak is adjusted by varying the energy of
the beam before it enters the gantry (Fig. 3.3) [16] [25].
In nearly all cases, scanning does not require any collimator, compensator, or other
beam-modifying device. A narrow mono-energetic beam paints the target volume in
layers, steered by magnets. Typically with scanning, there are no modifying devices to
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Figure 3.3: Scanning diagram
custom-make or store after treatment, making scanning a greener treatment option.
Without scattering material, scanning nat-
urally produces fewer neutrons and reduces
the integral dose to the patient. The
smaller the treatment volume and the lower
the integral dose, the better the patient is
likely to tolerate treatment. Proton ther-
apy delivers lower doses to healthy tissue
than external beam therapy with X rays,
and scanning delivers a lower dose than
other proton delivery methods.
Scanning makes IMPT possible. With scanning, dose distributions can be varied voxel
by voxel. By varying the beam intensity or the speed of scan, or both, dose is painted
non uniformly on a field-by-field basis to yeld an overall uniform target dose.
3.2 Carbon ion radiobiology
The use of carbon ions in radiotherapy has many potential advantages, arising both from
the physical aspects of their energy deposition and from biological phenomena resulting
from the high density of energy deposition. In contrast to conventional photon radiations,
where the dose distribution in the patient is primarily characterized by an exponential
decline in dose with depth, charged particles present a phenomenon known as the Bragg
peak. Particles at high energy deposit relatively little energy as they enter an absorbing
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material but tend to deposit extremely large amounts of energy in a very narrow peak,
the Bragg peak, as they reach the end of their range (Fig. 3.4) [13]. The depth and
magnitude of this Bragg peak is determined by the mass and charge, as well as the initial
energy of the particle.
For carbon ions, the high rate of energy loss towards the end of the particle range results
in a dramatic increase of the LET. While the Bragg peak is extremely narrow for a mo-
noenergetic beam of particles, a variety of techniques can be used to moderate the energy
and thus the range of the incident particles. The layering of a succession of Bragg peaks
with varying intensity can thus result in the spreading of high dose over a sufficiently wide
region to encompass a target volume (tumour) at a selected depth (SOBP) (Fig. 3.4).
Spreading of the Bragg peak results in a lowering of the average LET over the SOBP, but
this LET is still much higher than for photons and also for the particles in the entrance
region of the beam. The result of all this is that the absorbed dose distribution of ions
is as good as or better than that of protons, and superior to that of photons. When the
biologically weighted absorbed dose is considered, this superiority is further enhanced.
The high LET seen at the end of particle ranges not only affects the absorbed dose
distribution, but also marks consequences for the response of biological systems to that
dose. Among these known biological consequences there is a reduction in the oxygen en-
hancement ratio (OER) and in cell cycle sensitivity variation seen with photon radiation.
Reduction in the OER may represent an advantage in the treatment of certain tumour
types, suspected of possessing radiation resistant regions containing hypoxic cells. Re-
duction in the variation of cell cycle sensitivity may also be advantageous in the tratment
of certain tumour types, notably slowly growing tumours.
In addition to a reduction in the OER and in variation in cell cycle sensitivity seen with
ion radiation, a major advantage or concern with the use of high LET radiations is their
increased efficiency in producing cell death and a variety of other biological phenomena.
This may be an advantagewhen considering the absorbed dose in the cancer cell popu-
lation, and a disadvantage when considering the absorbed dose in normal tissue. Both
issues are of concern. The concept of RBE has been introduced to account for the in-
creased efficiency of high LET radiation if compared to photons. As defined, the RBE is
a simple concept, however, its apparent simplicity is deceptive. RBE cannot be uniquely
defined for a given radiation. The RBE of a given radiation type will vary with particle
type and energy, dose, dose per fraction, degree of oxygenation, cell or tissue type, bio-
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Figure 3.4: Comparison of the absorbed dose and isoeffective dose variations with depth
in a carbon ion beam. Carbon ion irradiation of a PTV located between 100 and 160 mm
in depth using a 290 MeV/amu beam. The RBE of a carbon beam increases significantly
with depth. Therefore, in order to obtain a uniform isoeffective dose (plateau) across the
SOBP, the absorbed dose needs to be adapted (modulated) and decrease with depth.
47
Chapter3. Hadron therapy treatment planning
logical end point, etc. The case of ion irradiation is particularly complex and the RBE is
a strong function of position within the treatment beam.
3.2.1 Increased RBE
RBE values for various high LET radiations have been determined for many biological
systems, and a great number of generalizations can be drawn from the results.
The first of these generalizations is that RBE tends to increase with increasing LET. As
energy decreases, LET increases for all particles, so a second generalization is that, for
any particle, RBE generally increases as particle energy decreases, except in the region
of "overkill".
Fig. 3.5 shows RBE values as a function of LET for cell survival, measured for two cell
lines using three different ion beams at different points in SOBPs. Once again, RBE
increases with LET but appears to reach a maximum at LET values of approximately
100-200 keV/µm before declining in the "overkill" region where the amount of energy
deposited in a cell by a single particle traversal is more than the amount required to kill
the cell. Fig. 3.6 also shows variation in RBE as a function of LET at various point in
SOBPs of carbon, neon, silicon and argon ion. Once again, RBE is seen to peak for LET
values of approximately 100-300 keV/µm [13].
Figures 3.5 and 3.6 [13] both demonstrate that even at the same value of LET∞, RBE
is a function of ion type. This is a result of differences in the fine structure of energy
deposition for different particle types even at the same LET and indicates that LET,
while often adequate, is not a perfect predictor for RBE.
In addition to increasing when LET increases and when particle energy decreases, RBE
also increases with decreasing dose per fraction (this is essential for partial treatment
considerations) and is higher for some late responding tissues than for early responding
ones. These findings can be assumed to apply to all tissues irradiaed with high LET
radiations and in particular, to a greater or lesser extent, to all tumour or normal tissues
in the SOBP region of an ion beam.
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Figure 3.5: RBE of cell survival for T-1 and R2D2 cells as a function of LET measured
at various points in SOBPs for carbon, neon and argon ions. The cells were irradiated
under aerobic conditions and the end point was 10% cell survived.
49
Chapter3. Hadron therapy treatment planning
Figure 3.6: Variation of OER as a function of LET measured at various points in SOBPs
of carbon, neon, silicon and argon ions.
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3.2.2 Rationale for ion therapy
The potential advantages of ions can be summarized in four points [13]
• The physical selectivity of ion beams is comparable to, or better than, the best
low LET therapy techniques. The penumbra is narrow and the dose ratio between
the SOBP and entrance plateau is better than with the best low LET radiation
(protons). Nuclear fragmentation of the ion beams is a potential disadvantage
because some energy is deposited beyond the Bragg peak. However, this aspect is
probably not clinically significant because the dose is low and the fragments are
lower LET particles.
• The LET in the ion beam, and consequently the RBE, increases with depth, and
this increases the ratio of the biologically weighted doses between the SOBP and
the entrance plateau. The RBE is comparable to neutrons, but the physical dose
selectivity is vastly improved for ions.
• At the level of the SOBP, where the PTV is located, high LET makes heavy ion
beams specifically effective for the tratment of some tumour types that are resistant
to low LET radiation.
• After fractionated irradiation, there is reduced possibility for repair for cells in the
PTV located in the SOBP, because the LET is highest there. In contrast the normal
tissues located outside the SOBP, in the entrance plateau region, are exposed to
lower LET radiation and thus may benefit from an increased repair opportunity.
Therefore, from a radiobiological point of view, fractionation in ion therapy should
bring a significant advantage and should be exploited. It is recognized, however,
that this radiobiological advantage may be balanced by the advantage of reducing
treatment times to reduce the effect of tumour cell repopulation, and also by some
economic considerations.
While ions appear to have potential advantages for the treatment of many tumour types,
it would be wise to use some caution. It has been pointed out that the physical dose in
the SOBP is significantly greater than in the entrance plateau and that the biological
weighting factor will increase the effect of this dose, due to the high LET in the SOBP. It
has also been pointed out that LET increases with depth in the SOBP. All of the above
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would appear to be advantages for the treatment of tumours wholly contained within
the SOBP. However, it cannot be assumed that the radiobiological effects seen in the
entrance plateau, where the LET may be in excess of 20kev/µm, are characteristic of low
LET radiations.
Table 3.1 [13] shows RBE values measured for several biological systems at several points
in a spread out beam of carbon ions as well as at the entrance. The table indicates that
RBE increases with depth in the SOBP but also shows a very high value for RBE in
the entrance region. The apparently high RBE value shown in the entrance region was
derived from a preliminary skin experiment and more recent experiments suggest that
the RBE in the entrance region is approximately 1.5, in agreement with the data shown
in figure 3.5. Both indicate that care must be taken in assuming values of RBE in the
entrance region of an ion beam. In addition, the RBE in the entrance plateau may be a
function of the type of scattering and beam modulation used with any ion beam.
Position LET 1 (keV/µm)
RBE values
Single fraction Four fraction
Cell culture Skin reaction Skin reaction
Entrance SOBP (6 cm) 22 1.8 2.0 -
Proximal 42 2.1 2.1 2.3
45 2.2 2.2 -
Middle 48 2.2 2.3 -
55 2.4 2.3 -
Distal 65 2.6 2.3 2.9
80a 2.8 2.4 3.1
Distal fall-off 100 - - 3.5
Table 3.1: RBE values of modulated 290 MeV/amu carbon ions beams of the heavy ion
medical accelerator relative to photon radiation.
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3.3 The Local Effect Model
Complex models are needed in hadron therapy to predict the biological effect of radiation
in order to make a rigorous treatment planning. However, the complexity of the radio-
chemical and radio-biological mechanisms involved in the formation of biological damage
complicates the creation of such models. Nowadays the model used at CNAO is the local
effect model, LEM [14][15].
The Local Effect Model aims to derive the biological effects of ion radiation from the
response of cells or tissues to photon radiation, thus efficiently exploiting the large data
base collected with conventional radiation. It makes use of the concept of the "local
dose", which is defined as the expectation value of the energy deposition at any position
in the radiation field for a given pattern of particle trajectories. The main assumption
of the LEM is that equal local doses should lead to equal local effects, independent on
the radiation quality. This local dose is derived from an amorphous track structure
representation of the energy deposition as a function of the radial distance to the particle
trajectory. The effectiveness of particles is thus calculated based on the microscopic local
dose distribution pattern of ion traversals within the cell nucleus, assuming the nucleus
to be the sensitive target for the observed radiation effects. (Fig. 3.7) [6].
In the first implementation of the model (LEM I) (Scholz et al. 1997) the local biological
effect for a local dose dloc is derived directly from the corresponding photon dose response
curve denoted as Sγ(D), where S represents the survival at dose D. This response curve is
represented by the linear-quadratic (LQ) parameters αγ and βγ for the specific biological
endpoint under consideration, which are known from experiments or clinical data. Since
the linear-quadratic description is only valid for doses in the order of 5 – 10 Gy (Astrahan
2008), a correction for S(D) was introduced in order to account for a transition to a linear
shape at higher doses D > Dt , where Dt denotes the "threshold" dose for the transition.
For the prediction of cell killing, the biological effectiveness of any ion radiation field can
then be derived from the quantity
¯Nl,ion =
∫
− lnSX(d(x, y, z))
Vnuc
dVnuc (3.1)
where SX(D) represents the effect after photon radiation as a function of dose D, d(x,y,z) is
the distribution of the local dose within the critical target, assumed to be the cell nucleus,
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Figure 3.7: Comparison of the microscopic local dose distributions of carbon ions and
photons for the same macroscopic dose of 2 Gy. For a random distribution of particle
traversals through a cell as depicted in (a) the corresponding local dose distribution is
characterized by extremely high spikes close to the particle trajectory (b). In contrast,
for photons the distributions is expected to be flat (c). Locally, i.e. in nm dimensions,
the distributions of particles can also be approximated by a flat distribution (d), thus
allowing the link to the photon distribution.
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and Vnuc is the volume of the cell nucleus. The term − lnSX(D) can be interpreted as the
mean number of lethal events produced per cell by photons at a dose D; the integrand in
eq. 3.1 thus represents a local density of lethal events at a given position (x,y,z) in the
nucleus. Integration of this event density over the volume of the nucleus for a given local
dose distribution pattern deposited by particle traversals results in the mean number of
lethal events Nl,ion per cell induced by these traversals.
Assuming a Poissonian distribution of the number of lethal events around this mean
value, the surviving fraction is determined by the fraction of cells with no lethal events
and thus by
Sion = e
− ¯Nl,ion (3.2)
By comparison with the photon dose Dγ leading to the same survival, i.e. Sγ = Sion,
RBE values can then be derived from
RBE =
Dγ
Dion
∣∣∣
isoeffect
(3.3)
The full integration would be too time consuming for purposes of therapy planning; there-
fore, approximations have been introduced, which are described in more detail in (Scholz
et al. 1997, Krämer et al. 2000b, Scholz et al. 2006).
Although the predictions of the LEM I were in reasonable agreement with experimental
and clinical data, e.g. for carbon ion irradiation in a spread-out Bragg peak (SOBP),
where deviations were in the order of 10-20% for therapy relevant conditions, larger sys-
tematic deviations were observed for high-energy, low-LET ions and lighter ions, e.g.
protons or helium ions, when using the model parameters optimized for the description
of carbon ions. Consequently, improvements have been implemented, aiming at reducing
these systematic differences. In the LEM II (Elsässer et al. 2007), the increased yield
of DSB, resulting from the induction of DNA single strand breaks in close vicinity (<25
base pair, bp), is taken into account, leading to a further enhancement of the biological
effects at very high local doses (>1000 Gy). Furthermore, since a considerable fraction of
the biological damage is induced by the indirect effect, the effects of radical diffusion have
been considered in more detail in the LEM II, that led to a “wash out” of the extremely
spiked local dose distribution in the particle track center.
A further refinement was achieved with the implementation of a more detailed track struc-
ture description, now including an energy dependent extension of the track core (LEM
III, (Elsässer et al. 2008)). This dependence on energy further increased the gradient of
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RBE along the penetration depth and, with that, led to a better agreement of the model
predictions with experimental data.
A key feature of the earlier versions LEM I-LEM III as described above is the direct link
between local dose deposition pattern and the photon dose response curve the observable
endpoint under consideration. In the recently reported extension (LEM IV, (Elsässer et
al. 2010)), an intermediate step is introduced, on the premise that a cell final biological
response to radiation is directly linked to the initial spatial DNA damage distribution
induced by radiation rather than the local dose distribution itself. We assume that the
microscopic spatial distribution of DNA damage, namely double strand breaks (DSB)
and in particular their local density, represents the relevant measure determining the fate
of a cell after radiation insult. Furthermore, in line with the general concepts of the LEM,
we assume that similar DSB patterns should lead to similar effects, independent of the
radiation quality leading to these patterns.
Although of course a strong correlation between the energy deposition pattern and the
spatial damage distribution pattern is expected and thus the distinction made above
seems to be quite subtle, actually under certain conditions these two views lead to sig-
nificantly different conclusions. This can be illustrated by means of the examples shown
in Fig. 3.8 [6].
The figure schematically compares the microscopic dose distribution (left side) respec-
tively for low and high energetic carbon ions of comparable macroscopic dose levels,
respectively, with the corresponding distribution of double strand breaks. Having very
high LET, the local dose distribution for low energetic ions is extremely peaked, and the
high number of DSB are concentrated along the particle trajectory, as a result of the
extremely high local dose deposition and the narrow track diamater. Here, both the high
local dose distribution as well as the clustered DSB distribution intuitively indicate an
enhanced effectiveness of the carbon ions. This picture changes when analyzing distribu-
tions for the high energetic ions. Here, the local dose still shows significant peaks at the
center of the individual tracks, although the space between individual tracks is now filled
with a "bath" of low local doses which originate from the overlap of the individual tracks
outer regions, which have a comparably large diameter at these high energies. However,
assuming that, for example, at these low LET values an individual particle produces only
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Figure 3.8: Schematic comparison of the local dose distributions (left) and correspond-
ing spatial DSB distributions (right) for low energetic (top) and high energetic (bottom)
carbon ions. Assumed DSB yields are 50 DSB and 0.5 DSB for the low energetic and
high energetic ions, respectively.
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0.5 DSB on average, the resulting pattern of DSB obeys a random distribution according
to the random pattern of particle traversals. Now, different conclusions can be drawn
from the local dose deposition pattern and the DSB pattern. The spikes in the local dose
distribution would still suggest an increased effectiveness of the particles. However, since
the DSB pattern is random, it cannot be distinguished from the pattern that would be
induced by photon radiation, and thus the same effectiveness is expected on the basis
of the DSB distribution. Since the cell actually responds to the damage induced by the
particle traversals, but not directly to the energy deposition, the spatial DSB distribution
pattern is considered to be the more relevant measure to assess the effectiveness of differ-
ent radiation qualities. The induction of clustered damages is an important aspect that
is reflected in the spatial DSB distribution pattern. In order to assess the similarity of
DSB distributions, specific measures have to be defined. In the LEM IV, these are related
to the structure of chromatin organization in the cell nucleus. It is assumed that the so
called "giant loops" of DNA (Yokota et al. 1995, Solovjeva et al. 1998), comprising about
2 Megabase pairs (Mbp) of DNA length, represent the critical structure of DNA (Osta-
shevsky1998, Johnston et al. 1998). We then distinguish two types of damage: when a
single DSB is induced in such a loop structure ("isolated DSB", iDSB), and when two
or more DSB are induced ("clustered DSB", cDSB). It is hypothesized that cDSB leads
to a significant higher probability of cell killing if compared to iDSB, since for iDSB the
DNA on both sides of the DSB is still attached to the nuclear matrix, and thus repair is
expected to be facilitated in this case. In contrast, for cDSB one or more DNA fragments
can be removed from the loop, being no longer attached to the nuclear matrix and thus
difficult to repair.(Fig. 3.9).
Assuming that induced damage in different DNA loops can be considered to act inde-
pendently, the total number of loops with iDSB and cDSB represents a measure of the
clustering of the DSB induced by a given dose deposition, as defined by the cluster-index
C:
C =
NcDSB
NiDSB +NcDSB
(3.4)
where NcDSB and NiDSB represent respectively the number of loops with isolated and
clustered DSB.
Calculation of the spatial DSB distribution is based on the local dose derived from the
radial dose profile described above and used already for the previous versions of the LEM.
Assuming a homogenous distribution of the DNA within the nucleus as a first approxi-
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Figure 3.9: Schematic representation of the chromatin giant loop structure (adapted
from Yokota et al.) and the consequence of isolated or clustered DSB within loops. For
simplicity, only the essential topology of chromatin loop structure is shown; the actual
conformation of individual loops includes additional complicated 3-dimensional folding.
mation, the mean number of DSB in any small subvolume of the nucleus can be derived
from experimental photon data, which indicate that the yield of radiation-induced DSB
is approximately 30 DSB/Gy/cell. Based on the local average number of DSB, spatial
DSB distributions are then determined by means of Monte-Carlo techniques, i.e. actual
DSB distributions are determined by considering the amorphous track structure pattern
as the probability density distribution of DSB.
Assuming a homogenous distribution of DNA within the nucleus, the amount of DNA
contained in a loop (approx. 2 Mbp) can be attributed to a subvolume of the nucleus,
based on the knowledge of the total DNA content (approx. 6× 109 Mbp in mammalian
cells) and the typical volume of the nucleus (approx. 500 µm3 ). In order to determine
the number of isolated and clustered DSB, the cell nucleus is divided into cubic shaped
subvolumes with 540 nm side length, corresponding to the volume covered by a 2 Mbp
DNA content when assuming a homogenous distribution of DNA within the nucleus. The
number of DSB in each subvolume is determined according to the local dose distribution
within the subvolume, and the subvolumes are then classified as isolated DSB or clustered
DSB if exactly one DSB or two or more DSB are induced in a subvolume, respectively.
In order to determine the biological effect of a given spatial DSB pattern, in a first step
the photon dose that leads to the same damage complexity C, i.e. the same relative com-
position of iDSB and cDSB, is determined. In a second step, the effect produced by that
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photon dose is appropriately scaled according to the total number of iDSB or cDSB that
are induced by a particle traversal and the photon dose, respectively. As a result, the
number of lethal events induced by a single particle traversal is obtained. This procedure
allows calculation of the effect of a single particle traversal, defining the effectiveness at
low doses and thus the αI term of the linear-quadratic representation of the dose response
curve. The βI-term can then be estimated according to the approximation described in
(Krämer et al. 2006). This approximation has been introduced since full simulations of
dose response curves would be infeasible for applications in the framework of treatment
planning; this was mainly due to the extremely time consuming calculations.
The concept of LEM IV also allows implementation of a detailed, full simulation for ar-
bitrary random particle traversal patterns (Friedrich et al. 2012). Compared to single
particle approximations, higher β-values are typically predicted in the intermediate LET
region, and work is in progress to analyse in more detail the impact of these differences on
the level of track-segment conditions as well as for clinical applications using spread-out
Bragg peaks.
For treatment planning, an accurate prediction of RBE for tumor cell killing and normal
tissue effects is essential. The model has thus been validated based on large experimental
data sets (Elsässer et al. 2008, Elsässer et al. 2010, Friedrich et al. 2012b). Fig. 3.10
shows a comparison of model predictions with experimental data obtained with helium
and carbon ions for the different model versions. Interestingly, the model improvements
had little effect on the shape of the RBE-LET-relationship at high LET values beyond the
maximum of RBE. The main impact is observed in the rising part of the RBE-LET-curve,
where essentially the gradient is affected, which consequently also affects the rise of RBE
with penetration depth in a typical spread out Bragg peak (SOBP). In general, for the
most recent implementation (LEM IV) a very good agreement is observed between the
predictions and the experimental data.
Compared to normal tissue toxicity, application of the LEM needs some generalization
because typically normal tissue responses cannot be easily traced back to effects of cell
killing, in particular for tissues like CNS where cell proliferation normally does not occur
and thus cell survival is not defined in the sense of the clonogenic assay. However, dose
response curves for normal tissue effects also typically can be described in terms of the
linear-quadratic model, and thus hypothetical “survival” curves can be constructed from
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Figure 3.10: Comparison of RBE predictions for different LEM versions with experi-
mental data for He irradition (top) and C irradation (bottom). Experimental data were
taken from Furusawa et al. (2000).
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Figure 3.11: Predictions of LEM I and LEM IV for the RBE for the tolerance of the rat
spinal cord in comparison to experimental data reported by Karger et al. Redrawn after
Grün et al., PMB 2012. Vertical bars for experimental RBE values represent error bars;
vertical bars for LEM calculations represent uncertainties due to positioning uncertainties
of +/- 1mm of the spinal cord and the RBE gradient within the spread-out Bragg peak.
the known α, β or α/β -values, and then the corresponding RBE values can be calculated
in analogy to the procedure applied for cell killing. Since the CNS represents a critical
tissue which frequently limits the dose given to the tumor, such as in the case of head and
neck tumors, as they were mainly treated within the pilot project, tolerance of the spinal
cord has been studied in pre-clinical in-vivo experiments (Debus et al. 2003, Karger et
al. 2006). Fig. 3.11 presents a comparison of the RBE values predicted by the LEM
IV, assuming an α/β-value for photon radiation of 2 Gy, with the experimental data as
reported by Karger et al. (2006). A significant improvement is achieved with the most
recent implementation of the LEM (Grün et al. 2012).
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The aim of my thesis was to study the effect of partial irradiation on real patients treated
with carbon ions at CNAO. Several quantities contribute to the effectiveness of a treat-
ment and are taken into account by each Treatment Planning System to provide the
optimum irradiation setup.
4.1 The Treatment Planning System
The TPS is a software which helps the physician to perform the treatment planning, via
the simulation and visualization of different irradiation scenarios and the capability to
search for optimal solutions. It is a complex tool, which receives as input the information
on patient anatomy as provided by the Computer Tomography (CT) data, the delineation
of the target and of the surrounding organs, the beam set-up and the prescription of the
wanted effect, and performs an inverse planning. The TPS task is completed when it
finds the set of beamlets intensities, energies and directions necessary to satisfy at best
the prescription.
This is not an easy task, in carbon ion therapy a uniform damaging of tumour cells is
not obtained by simply requiring a constant dose delivery on the target, because a flat
dose SOBP does not necessarily correspond to a flat biological effect. In fact, the infor-
mation of delivered dose alone is not sufficient to determine the biological effectiveness
of a carbon ion beam: a beam composed by ions of low kinetic energy is more efficient
in inactivating cells than another beam depositing the same dose but with ions of higher
kinetic energy, for the reasons explained in the thesis. Since the beam characteristics
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(distribution of kinetic energies and ion species) change during tissue penetration (due
to energy loss, energy loss straggling and fragmentation) and since in each point a su-
perposition of many beams occurs, the TPS must compute the inactivation probability
relative to the cells in a certain location on the basis of the statistical knowledge of how
many and which particles have passed by.
The TPS seeks the solution in an iterative way: starting from an initial hypothesis on the
beamlets intensities, the program computes for each point of interest the particles spectra
and estimates the corresponding biological effect; if the result satisfies the prescription,
then the TPS can terminate the execution and return to the physician the information
on the used beams; otherwise, the program must vary opportunely the beams intensities
and repeat the biological effect evaluation, until the specifications are met or the maxi-
mum number of iterations is reached. It is important to underline that the physician will
typically specify conflicting prescriptions, since he desires to escalate the dose over the
tumour, in the meantime asking to maintain limited the dose in the entrance path and
over the surrounding organs. Therefore, the mathematical cost function that quantifies
the distance of a certain irradiation effect from what the physician required is generally
non-linear and complex, and needs to be treated in the field of multi-objective optimiza-
tion.
It is also required that the evaluation lasts a reasonable time, of the order of minutes, so
that the TPS can constitute an interactive tool for the radiotherapist. The medical physi-
cist can then use it to run several trials, enforcing more or less restricted prescriptions. To
achieve these fast elaboration capabilities, the TPS usually relies on approximate models
or on pre-computed results, both for physical and radiobiological evaluation purposes. As
already underlined, the radiobiological effects estimate is one of the biggest conceptual
problems that the TPS has to face.
The TPS in use at CNAO is provided by Siemens and its commercial name is Syngo
RT Planning, which is also in clinical use at the Heidelberg Ion Therapy Center (HIT),
Germany. Siemens software, in 2011, when the CNAO started the clinical treatments, was
the unique available CE certified commercial product, able to elaborate treatment plans
for protons and carbon ions beams delivered with the modulated scanning technique.
It is a very sophisticated software, whose main task is to calculate optimal treatment
solutions. It is able to acquire patient anatomical data (through TAC images or MR),
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convert data from TAC in water-equivalent material, simulate and optimize the absorbed
and effective dose distribution in the region of interest. Beyond many other features, the
software main task is to produce treatment plans structured on three steps:
• Read the patient’s CT-data
• Choose the positions of the pencil beams within the target
• Determine for each pencil beam the number of particles necessary to produce a dose
distribution according to the prescribed dose.
TPSs for hadron therapy are typically based on analytical codes and external databases
for the description of nuclear and electromagnetic interactions of hadrons in water. A
large database is requested so it is necessary to integrate measurements with Monte Carlo
simulations. The most relevant data for hadron therapy are:
• DDD (Depth Dose Distribution).
• Lateral dose profile of individual pencil beams.
• Conversion tables between Hounsfield Units (HU) and range in water, which permit
the reading of CT images.
Moreover we describe here some additional inputs:
CT-data and VOIs. An important input to each TPS is the CT image of the patient.
Resolution of CT is usually about 1 mm in x- and y-direction and 3 mm in z-
direction, which is the thickness of a CT slice. Such an elementary volume having
these dimensions is called voxel. To every voxel is assigned one value: the Hounsfield
Unit (HU), which represents the X-ray attenuation in a material and it can be
related to the density of that voxel. The HU s are defined as:
HU =
(
µ̄
µ̄H2O
− 1
)
· 1000 (4.1)
where µ̄ and µ̄H2O are the mean values of the attenuation coefficient of tissue and
water, respectively. Therefore the CT number is a CT-scanner- dependent quantity
with fixed values for water, 0, and air, -1000. Using an external database, i.e.
water equivalent path length (WEPL) versus HU, the TPS calculates Bragg peak
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positions on the CT of the patient. Additional information needed by the software
are the positions and the volumes of the target and of the critical structures, which
are called VOIs (Volume Of Interest). Each VOI, for example the tumor, is defined
in each CT slice by a physician. VOIs may also be defined in healthy tissue,
representing critical structures like the brain stem or the optical nerve. This critical
structures are called OAR (Organ At Risk).
RBE-table. The RBE-tables contain all data relevant to calculate the biological effective
dose for a certain tissue type, as a function of energy and particle species. With these
informations the biological effect for complex ion fields can be evaluated according
to the LEM model, described in chapter 3. For proton beam the RBE-value is fixed
at value 1.1.
Accelerator-table. The accelerator-table provides to the TPS the available energies
and associated focus, i.e. dimensions, and intensities. Beam fluence optimization is
based on the information in this table. At CNAO are available 147 energies. The
energy range for Carbon ion beams is 120-400 MeV/u, for proton beams the energy
ranges from 63 MeV up to 250 MeV,
Dose values. As a result of the treatment planning a dose matrix contains the 3D-dose
distributions of biological dose.
Dose volume histogram. Instead of inspecting the entire CT to access the quality
of a treatment plan, a DVH (Dose Volume Histogram) allows fast control of the
optimization results. Percentage of a volume is plotted versus received dose (see
Fig. 4.1).
4.1.1 DEK
DEK, Dose Engine Kernel, is basically a proton/carbon ion TPS kernel developed and
validated by INFN of Torino, in collaboration with the Ion Beam Application (IBA)
Company [19]. This kernel is focused on spot scanning techniques. It is able to com-
pute the physical and radiobiological effectiveness of a certain treatment configuration,
accepting as inputs the anatomy of the patient and the beams set-up (forward planning).
Additionally, DEK provides the inverse planning process to create the optimum beams
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Figure 4.1: Example of Dose Volume Histogram performed by Syngo.
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characteristics starting from the physician’s prescription and different inputs defined by
the user.
The DEK is a TPS kernel in the sense that performs the TPS core computations, while
it is not intended to provide a graphical interface nor any support for setting patient con-
tours, beams configuration and prescription. Instead, these features have been a crucial
part of my work to use DEK to study the partial doses. DEK has been chosen because
of its versatility and availability as a research tool at the INFN of Torino.
DEK is a code able to estimate the probability of cell survival in each volume element
traversed by the beam, depending on the characteristics of both ion beams and tissue.
DEK allows the forward dose calculation and the following quantities can be saved and
studied:
Physical dose: Hadron absorbed dose is a physical dose quantity D representing the
mean energy imparted to matter per unit mass by ionizing radiation.
D =
dε̄
dm
(4.2)
The International System of units uses Gray [Gy] to measure the absorbed dose
and 1 Gy corresponds to 1J/1kg, joules per kilogram.
The physical dose given to each voxel {i, j, k} of the computing grid selected within
the CT volume, is the superposition of the dose delivered by all the beams l which
pass through it:
Dijkl = φlD
(0)
ijkl (4.3)
where φl is the fluence of the l beam, and the total dose is
Dijk =
∑
l
Dijkl (4.4)
RBE: The relative biological effectiveness, RBE, is defined as the ratio of the dose DX
administered with X rays and the dose D given with ions that correspond to the
same cell survival S. The RBE is an empirical value that varies depending on the
particles, energies involved, and which biological effects are observed.
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The relative biological effectiveness for radiation of type R on a tissue of type T is
traditionally defined as the ratio
RBE =
DX
DR
(4.5)
where DX is a reference absorbed dose of radiation of a standard type X, usually
the dose of X-rays of 250 kV, and DR is the absorbed dose of radiation of type R
that causes the same amount of biological damage. Both doses are quantified by
the amount of energy absorbed in the cells.
The knowledge of the carbon ions RBE becomes essential for the calculation of the
biological dose. We saw in the previous chapter the complexity of the RBE due to
its dependence on the dose itself, the LET and several other factors.
The RBE provides a mathematical framework to compare different treatment modal-
ities. It refers to the isoeffective ratio of the dose deposited by a reference radiation
to that of carbon ion irradiation in one fraction, dp (with p standing for particle).
In the context of the linear quadratic model, the RBE can be calculated using the
LQ-parameters αp and βp for particles and αX and βX for the reference radiation
(x-rays),
RBE =
−αX +
√
α2X − 4βX(αpdp + βpd2p)
2βXdp
(4.6)
The induced cellular damage, and thus the LQ-model parameters, strongly depends
on the linear energy transfer of the respective radiation. The parameters αp and
βp for each ion type and energy level are estimated from biological modeling ap-
proaches, e.g, the local effect model (LEM) described in the previous chapter.
For an accurate modeling of both, the delivered physical dose and the biological
effectiveness of a carbon ion beam, it is essential to consider its specific fragment
and energy spectrum. For a multienergetic beam of energies E, constituting of a
range of fragments Z, αp and βp at each voxel i in a patient are the dose averaged
sum of the contributions from each pristine Bragg peak,
αp(i) =
∑
Z
∫∞
0
α(Z,E) · Φ(i, Z, E) · Sp(Z,E)dE∑
Z
∫∞
0
Φ(i, Z, E) · Sp(Z,E)dE
(4.7)
√
βp(i) =
∑
Z
∫∞
0
β(Z,E) · Φ(i, Z, E) · Sp(Z,E)dE∑
Z
∫∞
0
Φ(i, Z, E) · Sp(Z,E)dE
(4.8)
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Here, Sp(Z,E) refers to the stopping power and the fragmenta spectra are denoted
by Φ(Z,E) Using this representation of the LQ-model parameters, the RBE as
given in Eq. 4.6 varies across the volume of interest.
Biological Dose: The biological dose defined as the product of hadron absorbed dose,
D, and hadron RBE
Dbio = D ×RBE (4.9)
is introduced to estimate the photon dose that would produce the same therapeutic
effect as the hadron absorbed dose, D, given under identical conditions.
Survival: In the context of the linear-quadratic model, the surviving fraction of clono-
genic cells in a tumor, S, is solely determined by the biological effect ε, wich can be
calculated for each voxel i:
S(ε) = eε, εi = αpidpi + βpid
2
pi
(4.10)
LET: The linear energy transfer, LET, describes the action of radiation upon matter. It
describes how much energy an ionising particle transfers to the material transversed
per unit distance. LET depends on the nature of the radiation as well as on the
material traversed.
L =
dE
dl
(4.11)
where dE is the local energy loss due to collisions for a charged particle along a
track segment dl. LET is habitually expressed in keV · µm−1.
The biological dose, the RBE and the survival distributions for total fraction irradiation
and for partial irradiations have been computed for 2 CNAO patients.
At present stage DEK is not able to read DICOM files. Inputs have to be written in
a proprietary format that will be specified in what follows. The evaluation results are
saved in proprietary files as well.
The DEK is entirely written in C++ and it is executed on a Linux machine.
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4.1.2 DICOM and DEK formats
Syngo generates a file with the characteristics of the beams used by the accelerator and
by the dose delivery to perform the treatment.
The standard TPS output files are in DICOM (Digital Imaging and Communications in
Medicin) which is the international standard for medical images and related information
(ISO 12052). It defines the formats for medical images that can be exchanged with the
data and quality necessary for clinical use. With tens of thousands of imaging devices in
use, DICOM is one of the most widely deployed healthcare messaging standards in the
world.
The RTPlan.dcm provided by the Syngo TPS with the beam’s characteristics has to be
converted into the "*.beams" format required by DEK to run. A dedicated MATLAB
script has been developed for this work, to create the "*.beams" files for different partial
irradiations, starting from the whole RTPlan.dcm.
The format of the "*.beams" file has to be the following:
The field numberOfBeams indicates the number of beams listed in the next rows, one for
each beam (or spot). The rows that follows are one for each spot. Each row contains:
• The (xiso, yiso, ziso) coordinates in mm of the isocenter in the CT reference system.
• The indication of the gantry orientation through the Gantry Angle.
• The indication of the patient orientation through the Patient Support Angle.
• The indication of the number of primaries delivered by the beam.
• The specification of nominal beam energy in MeV/u.
• The X- and Y-coordinates in the IEC Gantry reference system of the intersection
of the isocenter plane z = 0 with the beam axis.
• optional : the (xs , ys, zs) coordinates in mm of the beam spot position in the CT
reference frame; they can be omitted.
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By changing the number of beams or their characteristics we are able to study the effect
of these variations on the dose distributions using DEK calculation.
In the next paragraph the use of DEK to study the effect of partial irradiation is described.
4.2 Partial treatment delivery
In the treatment plan, the total dose is divided into fractions and each daily fraction is
usually characterized by one, two or three fields.
As I have described in section (3.1), the techniques for planning with active scanning
protons are the Single Field, Uniform Dose (SFUD) and Intensity Modulated Proton
Therapy (IMPT), that establish the number and characteristics of the fields. The former
is the combination of individually optimized fields, each delivering (more or less) homoge-
nous dose across the target volume. The latter is the simultaneous optimisation of all
Bragg peaks from all fields (with or without additional dose constraints to neighbouring
critical structures).
The dose fractionation optimize the cost-benefits ratio of the treatment plan.
4.2.1 Dose fractionation
Efficacy of fractionation is based on the so called 4 Rs:
• Repair of sublethal damage: Cells exposed to sparse radiation experience sublethal
injury that can be repaired, so cell killing requires a greater total dose when given
in several fractions. Fractionation allows for repair of injured normal tissue and
gives a potential therapeutic advantage over tumor cells.
• Reoxygenation: Hypoxic cells require more radiation to kill.
• Redistribution: Position in cell cycle at time of radiation determines sensitivity
– S phase is radioresistant
– G2 phase delay results in increased radiation resistance
Fractionated hadron therapy redistributes cells, rapidly cycling cells like mucosa,
skin are more sensitive, slower cyclers like connective tissue, brain are spared.
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• Repopulation: Determines the length and timing of therapy course
Dividing a dose into several fractions both spares normal tissues and damages the tu-
mor. Former there is repair of sublethal damage between dose fractions and cells are
able to repopulate. Latter there is a damage to the tumor because of the reoxygenation
of tumor environment and the reassortment of cells into radiosensitive phases of the cell
cycle between dose fraction. Prolongation of treatment reduces early reactions, however,
excessive prolongation allows surviving tumor cells to proliferate.
During a session, may happens that for some reason, for instance a patient related problem
or a machine failure, the total planned dose is not completely executed, in this case we
speak of partial dose irradiation.
If the missed dose will be delivered to the patient in another day the total physical
dose distribution over all the fractions will not change. The effects on biological dose
distributions are not trivial and a tool to investigate them would be useful for physicists
and physicians to take decisions. One goal of this work was to implement a research tool
based on DEK to easy evaluation of partial irradiation. The expected biological effects
are discussed in the next paragraph.
4.2.2 Dose recalculation
As mentioned before, DEK can compute the forward dose calculation from the Syngo
TPS planned beams parameters, using the "*.beams" files as input to DEK.
We can divide the beams files containing a certain number of fields in n subgroups, where
n is the number of the fields. The field is characterized by a specific value of the gantry
angle and patient support angle.
The output doses are stored in "*.values.3d" files (Fig 4.2), filled with the values of the
required quantities.
DEK can compute both the total and the partial treatment depending on the beams used
as input, while the Syngo TPS is not equipped with the Forward Computation option on
external input. This is why the work of this thesis is also an interesting work from the
clinical usefulness point of view.
The data in the values file are expressed as a 3D matrix, which elements contain the
measured quantity delivered to the corresponding voxel.
73
Chapter4. Material and methods
Figure 4.2: Example of a values file, format of the DEK output.
MATLAB scripts have been developed for graphical display of these radiobiological quan-
tities calculated by DEK.
We show the physical dose, the biological dose, the RBE, the cell survival fraction and
the LET for a CNAO patient (A140376) on one slice of the volume passing through the
isocenter, expressed in mm, in Fig. 4.3, 4.4, 4.5, 4.6 and 4.7 respectively. Thanks to DEK,
it is possible to consider the fields and their effects, both individually and combined.
In Fig 4.8 the dose distribution profiles for a single row of the central plane (representing
dose values in function of the increasing depth) can be seen. As expected, the physical
dose for combined fields equals the sum of the physical doses for each beam. Due to the
non linearity of RBE, however, the sum of biological doses calculated independently for
each beam is higher than the biological dose for the total planned irradiation.
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(a) Total
(b) Field A
(c) Field B
Figure 4.3: Physical dose [Gy] for total irradiation (a) and for the individual fields (b)
(c) of one slice of the volume [mm] (z = cost) through the isocenter. With DEK it is
possible to evaluate the absorbed dose released by each field individually. Note that the
path of entering radiation can be seen as a weaker trace before the target volume. One
beam being weaker than the other, in the graph for total delivered dose one of the tracks
is almost indestinguishable.
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(a) Total
(b) Field A
(c) Field B
Figure 4.4: Biological dose [Gy(RBE)] for total irradiation (a) and for the fields taken
into account individually (b) (c) of one slice of the volume [mm] (z = cost) through
the isocenter. With DEK it is possible to evaluate the biological dose released by each
field individually. Note that the path of entering radiation can be seen as a weaker trace
before the target volume. One beam being weaker than the other, in the graph for total
delivered dose one of the tracks is almost indestinguishable.
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(a) Total
(b) Field A
(c) Field B
Figure 4.5: RBE for total irradiation (a) and for the fields taken into account individu-
ally (b) (c) of one slice of the volume [mm] (z = cost) through the isocenter. With DEK
it is possible to evaluate the RBE released by each field individually. Note that RBE is
higher for B field due to its lower intensity.
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(a) Total
(b) Field A
(c) Field B
Figure 4.6: Cells survival fraction [%] for total irradiation (a) and for the fields taken
into account individually (b) (c) of one slice of the volume [mm] (z = cost) through the
isocenter. With DEK it is possible to evaluate the cell survival fraction for each field
individually.
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(a) Total
(b) Field A
(c) Field B
Figure 4.7: Dose averaged LET [Gy/µm] for total irradiation (a) and for the fields taken
into account individually (b) (c) of one slice of the volume [mm] (z = cost) through the
isocenter. With DEK it is possible to evaluate the LET of each field individually.
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(a) Physical dose
(b) Biological dose
(c) RBE
Figure 4.8: Physical dose [Gy] (a), biological dose [Gy(RBE)] (b) and RBE (c) profile
for a row of the central plane [mm] through the isocenter for total irradiation, the two
fields taken into account individually and the sum of the two fields. Note that because
of the different RBE, the sum of the biological dose of the two fields is greater than the
total irradiation.
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4.3 Dose Volume Histogram comparison
The purpose of my thesis is to build a tool to evaluate partial dose distributions and
compare them with the full planned dose.
The Dose Volume Histogram, DVH, allows graphic visualization of how much percentage
of the desired organ volume took at least a prescribed amount of dose, this allows the
doctor evaluating how good a dose distribution is. In the case of partial irradiation I
want to show how much the partial biological doses deviates form the total ones.
DVH summarizes 3D dose distributions in a graphical 2D format. In modern radiation
therapy, 3D dose distributions are typically created in a computerized TPS based on a
3D reconstruction of a CT scan. The "volumes" referred to in DVH analysis is a target
of radiation treatment, a healthy organ nearby a target, or an arbitrary structure [3].
DVHs can be visualized in either of two ways: differential DVHs or cumulative DVHs
(Fig. 4.9 shows an example). A DVH is created by first determining the size of the dose
bins of the histogram. Bins can be of arbitrary size, e.g. 0-1 Gy, 1.001-2 Gy, 2.001-3
Gy, etc. In a differential DVH, bar or column height indicates the volume of structure
receiving a dose given by the bin. Bin doses are along the horizontal axis, and structure
volumes (either percent or absolute volumes) are on the vertical. The differential DVH
takes the appearance of a typical histogram.
The cumulative DVH is plotted with bin doses along the horizontal axis, as well. How-
ever, the column height of the first bin (0-1 Gy, e.g.) represents the volume of structure
receiving greater than or equal to that dose. The column height of the second bin (1.001-2
Gy, e.g.) represents the volume of structure receiving greater than or equal to that dose,
etc. With very fine (small) bin sizes, the cumulative DVH takes on the appearance of a
smooth line graph. The lines always slope and start from top-left to bottom-right. For a
structure receiving a very homogenous dose (100% of the volume receiving exactly 10 Gy,
for example) the cumulative DVH will appear as a horizontal line at the top of the graph,
at 100% volume as plotted vertically, with a vertical drop at 10 Gy on the horizontal
axis.
A DVH used clinically usually includes all structures and targets of interest in the radio-
therapy plan, each line plotted with a different color, represents a different structure, as
shown in Fig. 4.9. The vertical axis is almost always plotted as percent volume (rather
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(a) Cumulative DVH
(b) Differential DVH
Figure 4.9: Example of a cumulative (a) and differential (b) DVH for the same plan.
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than absolute volume), as well. A drawback of the DVH methodology is that it offers
no spatial information, i.e., a DVH does not show where within a structure a dose is
received.
Structures and targets
As introduced in ICRU Reports 50, 62 71 and 78, several volumes and margins related to
both tumor and normal tissues have been defined for use in the treatment planning and
reporting processes. Delineation of these volumes is an obligatory step in the planning
process, as absorbed dose cannot be prescribed, recorded and reported without specifica-
tion of target volumes and volumes of normal tissues at risk.
The main defined volumes are:
• Gross tumour volume (GTV): the gross palpable or visible/demonstrable extent
and location of malignant growth. The tumour can be discovered by palpation and
application of different medical imaging methods.
• Clinical target volume (CTV): The clinical target volume is the volume that contains
a demonstrable GTV and/or sub-clinical microscopic malignant disease, which has
to be eliminated. This volume thus has to be treated adequately in order to achieve
the aim of therapy, cure or palliation. The CTV is an anatomical–clinical volume
and is usually determined by the radiation oncologist. The CTV is usually stated
as a fixed or variable margin around the GTV (e.g. CTV = GTV + 1 cm margin).
Margins will be added to the CTV to create the Planning Target Volume (PTV).
• Planning target volume (PTV): The planning target volume is a geometrical con-
cept, and it is defined to select appropriate beam arrangements, taking into con-
sideration the net effect of all possible geometrical variations, in order to ensure
that the prescribed dose is actually absorbed in the CTV. The PTV includes CTV
and an additional margin for set-up uncertainties (organ motion, systematic errors
caused by inaccuracy of patient positioning and machine tolerances). The PTV is
linked to the reference frame of the treatment machine and is often described as
the CTV plus a fixed or variable margin (e.g.PTV = CTV + 1 cm).
• Region of interest (ROI): The region of interest is a user defined region, which is
commonly abbreviated as ROI. In radiation therapy: normal tissues whose radiation
83
Chapter4. Material and methods
sensitivity may significantly influence treatment planning and/or prescribed dose.
ICRU 62 gives some new definitions:
• Internal margin (IM) - A margin that needs to be added to the Clinical Target
Volume (CTV) to form the Planning Target Volume (PTV) to account for any
positional errors from the planning information. ICRU Report 62 divided this
margin into the Set up Margin (SM) and Internal Margin (IM), in order to separate
the contributory sources of positional error into physiological error and set up error,
respectively. The IM compensates for physiological variation of the size and shape
of the volume (filling of rectum, movements due to respiration).
• Setup margin (SM) - The IM incorporates both intra-fraction errors such as that
due to respiration, and inter-fraction errors such as that due to weight gain/loss
or digestive system changes. SM accounts for all uncertainties in patient-beam
positioning and technical factors (patient immobilization, machine stability). The
total required margin is SM + IM.
• Internal target volume (ITV): accounts for motion of CTV in the patient, does
not account for setup uncertainties, ITV = CTV + IM. The PTV in the case
of conformal therapy and IMRT have to be determined with formula: PTV =
ITV+set-up errors (on the base of on-board imaging).
• Planning organ at risk volume (PRV): PRV = OAR + margin (accounts for OAR
movements). PTV and PRV may overlap.
I have analyzed the DVHs of some important structures of two CNAO patients. The
effect of partial irradiations has been estimated looking the DVHs of the absorbed dose
for the PTV and for some organs at risk separately as presented in the Chapter 5.
Patient A140376
The CNAO patient A140376 was treated to cure a chest wall sarcoma. The total pre-
scribed dose on the PTV is of 76.8 Gy(RBE), delivered in 16 fractions of 4.8 Gy(RBE)/day.
The total dose is delivered with two fields (field A and field B) perpendicular to each other.
The analysis of this patient is described in Chapter 5.
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Figure 4.10: Schematisation of some volumes of interest used in a treatment plan.
Patient A150769
The CNAO patient A150769 was treated to cure a a chordoma. The total prescribed
dose on the PTV is of 48 Gy(RBE), delivered in 16 fractions of 3 Gy(RBE)/day. The
total dose is delivered with two fields (field A and field B) with a Gantry angle of 90◦ for
both the fields and a Patient angle of 160◦ for the field A and 260◦ for the field B. The
analysis of this patient is described in Chapter 5.
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Results
The figures 5.1, 5.2, 5.5 and 5.6 show the DVHs of PTV for the physical and biological
dose for two CNAO patients, A140376 and A150769, in case of total treatment ("Total"
in the plots) superimposed to the cases of individual fields ("Field A" and "Field B" in
the plots) and to the case of the sum of single fields performed individually ("Field A +
Field B" in the plots). In figures 5.3, 5.4, 5.7 and 5.8 are represented the DVHs for the
organs at risk (it was taken as reference the liver for patient A140376 and the brain for
patient A150769).
The PTV and OAR DVHs that I have calculated show the main characteristic of carbon
ions: while the physical dose remains unchanged for the total case and for the sum of
the fields taken individually, the biological dose changes. This important carbon ion phe-
nomenon compared to photons and protons is explained by the fact that the physical dose
is proportional to the number of deposited particles (and the total number of particles
does not vary), while the biological dose, i.e. the physical RBE weighted dose, depends
on the dose itself. Specifically we expect greater biological effectiveness at lower doses,
and in fact the sum of the fields gives a higher biological dose than the total one.
Furthermore we have to remember that the technique used for the TPS is the intensity
modulated proton therapy, IMPT. This technique allows a good dose uniformity over the
tumor, as a result of the overlap of two or more not uniform fields, but the single field
taken individually is not at all uniform. Therefore from the figures we can see how the
DVHs of fields taken individually are covering in a different way the target. In particular
in both the analyzed patients, both the fields are required to deliver a uniform dose on
the PTV. Looking the Fig. 5.1 and 5.2 the shape and the maximum dose of the two fields
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are significantly different. For that reason if one field is not delivered in the scheduled
day it will be recovered in a dedicated additional day. The effect of the split of the Total
dose in two days can be seen in the curve "Field A + Field B" in the shown DVHs.
In the specific both A140376 and A150769 cases, we can conclude that field B is essential
in optimizing the TPS: it makes the dose on PTV uniform and is much less intense than
field A, thus gives greater biological effectiveness.
In Tab. 5.1, 5.2, 5.3 and 5.4 the differences between the different DVHs curves are
summarized. The therapy goal is to deliver the 100% of the prescribed dose to the 100%
of the tumor (or PTV in our figures). Lower values indicate low treatment efficacy. On
the contrary if the OAR are considered, the best should be 0 dose on 100% of the OAR
volumes. In that case the low dose values on small percentage of volume indicate low
toxicity and good treatment.
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Figure 5.1: PTV DVH of physical dose for patient A140376 in case of total and partial
treatment delivery.
Figure 5.2: PTV DVH of biological dose for patient A140376 in case of total and partial
treatment delivery.
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Figure 5.3: OAR (liver) DVH of physical dose for patient A140376 in case of total and
partial treatment delivery.
Figure 5.4: OAR (liver) DVH of biological dose for patient A140376 in case of total
and partial treatment delivery.
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Figure 5.5: PTV DVH of physical dose for patient A150769 in case of total and partial
treatment delivery.
Figure 5.6: PTV DVH of biological dose for patient A150769 in case of total and partial
treatment delivery.
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Figure 5.7: OAR (brain) DVH of physical dose for patient A150769 in case of total and
partial treatment delivery.
Figure 5.8: OAR (brain) DVH of biological dose for patient A150769 in case of total
and partial treatment delivery.
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Volume [%] Total [%] Field A+B [%] Field A [%] Field B [%]
95% 31% 34% 3% 11%
75% 42% 49% 17% 27%
50% 49% 58% 24% 33%
10% 55% 66% 35% 44%
5% 57% 68% 38% 49%
1% 61% 73% 45% 57%
Table 5.1: Some biological dose threshold values for PTV DVH for patient A140376 in
case of total and partial treatment delivery, expressed as relative dose respect the pre-
scribed one, assumed to be the max value of the biological dose, Dmax = 11.88Gy(RBE).
Volume [%] Total [%] Field A+B [%] Field A [%] Field B [%]
95% 1% 1% 0.1% 0%
75% 2% 2% 0.1% 3 · 10−2%
50% 3% 4% 2% 1%
10% 61% 70% 40% 24%
5% 73% 89% 48% 48%
1% 80% 98% 60% 59%
Table 5.2: Some physical dose threshold values for the OAR (liver) DVH for pa-
tient A140376 in case of total and partial treatment delivery, expressed as relative
dose respect the prescribed one, assumed to be the max value of the biological dose,
Dmax = 8.29Gy(RBE).
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Volume [%] Total [%] Field A+B [%] Field A [%] Field B [%]
95% 51% 52% 1% 45%
75% 56% 60% 3% 51%
50% 59% 64% 10% 54%
10% 69% 78% 21% 61%
5% 77% 84% 25% 75%
1% 91% 92% 31% 90%
Table 5.3: Some biological dose threshold values for PTV DVH for patient A150769 in
case of total and partial treatment delivery, expressed as relative dose respect the pre-
scribed one, assumed to be the max value of the biological dose, Dmax = 6.26Gy(RBE).
Volume [%] Total [%] Field A+B [%] Field A [%] Field B [%]
95% 0% 0% 0% 0%
75% 2 · 10−5% 2 · 10−5% 0% 0%
50% 0.05% 0.05% 2.3 · 10−3% 0.01%
10% 30% 30% 0.2% 28%
5% 44% 44% 2% 40%
1% 62% 64% 35% 56%
Table 5.4: Some biological dose threshold values for OAR (brain) DVH for pa-
tient A150769 in case of total and partial treatment delivery, expressed as relative
dose respect the prescribed one, assumed to be the max value of the biological dose,
Dmax = 4.11Gy(RBE).
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Conclusions
During a session, may happens that for some reason, for instance a patient related prob-
lem or a machine failure, the total planned dose is not completely executed, in this case
we speak of partial dose irradiation.
If the missed dose will be delivered to the patient in another day the total physical dose
distribution over all the fractions will not change. The effects on biological dose distri-
butions are not trivial and a tool to investigate them would be useful for physicists and
physicians to take decisions.
One goal of this work was to implement a research tool based on DEK to easy evaluation
of partial irradiation.
The codes developed in this thesis, written in MATLAB, made possible to automatically
vary the number of DEK input beams to calculate partial doses and to show in a Dose
Volume Histogram (DVH) the quality of the expected biological dose distribution for
different combinations of partial plans compared with the planned one.
DEK was chosen for its versatility, typical of research products, which allows to calculate
the following quantities: the physical dose [Gy], the Relative Biological Effectiveness,
RBE, in different tissues, the Biological Dose [Gy(RBE)], cell survival and distribution
of Linear Energy Transfer, LET, of the beams used.
The results show an increase of the biological dose in all cases of partial irradiation com-
pared to the physical one, in accordance with the RBE dependence on the dose that
appears to be greater for lower total doses. This agreement confirms the correctness of
the work, which is the starting point of a more complex instrument, capable of consider-
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ing different radiobiological models and all the variables used in them.
The study of the RBE as function of time is also currently studied by several research
group [12].
A model considering the properties of carbon ion RBE and its dependence on the time
would bring huge benefits in hadron therapy.
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Dose recalculation
The dose calculation is performed in R using a forward planning.
CT, contours and 3D data
Patient CT: Assuming to have in the ’./patient-data/CT/’ folder the sequence of DI-
COM images of patient CT, you can load into memory the complete CT with:
ct <- read.3d.dicom (dicom.folder = ’./patient-data/CT/’)
The command read.3d.dicom reads directly the CT from DICOM format. The CT is
assigned to the object ct.
3D data display (a slice): The objects of class values can be displayed with the family
of display.slice methods. For example, to display the Hounsfield numbers on an axial
slice for z = 180 mm:
display.slice (ct, z = 180, variable = ’HounsfieldNumber’)
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Data patient contours: For the tratment planning we need to identify the volumes
of interest (VOI) in CT. This is done by defining the boundaries that circumscribe the
VOI, on the axial slice. Rplanit does not have methods to directly define these boundaries
(except in the case of simple volumes), so you have to load them from files (DEK format):
contours <- read.contours (file.contours = ’patient-data / CM / cm.contours’, CT = ct)
Data Display + CT contours: Having loaded into memory the contours it is possible
display them overlapping on axial CT slice using an optional parameter in display.slice.ct :
display.slice.ct (ct = ct, contours = contours, HU.window = c (-150, 250), z = 180,
invert.y.axis = TRUE)
The contours are displayed in a single color (green by default). It is possible to use
different colors for each contour defining them directly in data.frame contours (this color
information is already present in DICOM, but not in the DEK format). For example
these colors are defined (one for each contour) and inserted into contours :
display.color <- rainbow (length (unique (contours$contour)))
contours$display.color <- display.color [contours$id + 1]
display.slice.ct (ct = ct, contours = contours, HU.window = c (-150, 250), z = 180,
invert.y.axis = TRUE, use.contour.colors = TRUE)
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Read / write 3D data and contours: For a more comfortable use CT (or generally
the 3D structures) can be saved locally in DEK format with the command:
write.3d (values = ct, file.name = ’ct.3d’) # write in file ’ct.3d’
ct <- read.3d (file.name = ’ct.3d’) # read 3D data in DEK format
Similarly for the contours you can use write.contours and read.contours commands. Gen-
erally it is always possible to use the save and load commands directly to save any object
in R format.
Treatment plan definition
To carry out the treatment planning we have to define some information.
R organizes this data in a specific data structure called plan. You can create a template
of this structure with this command, filled with default values:
plan <- create.plan(name = ’plan-example’)
Through create.plan command, defining the appropriate parameters it’s possible directly
associate data to their corresponding fields. Once the plan is created, these data can
also be added or changed later. In the above example the only data directly entered
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is the plan name. The plan name corresponds essentially to the folder name where the
simulation input and output data will be saved. For practical purposes it is sufficient to
know only the name of the plan to retrieve the required information. For example, to
save and load later the plan:
save.plan(plan) # the ’plan-example’ folder is created and filled
plan <- read.plan ( ’plan-reverse’)
Patient definition: Information of the patient’s geometry are contained in CT and con-
tours. It’s possible set these data "hooking" directly objects in ct and contours memory
to the respective plan slots:
plan$ct <- ct
plan$contours <- contours
In an alternative way it would be possible, instead of directly pass objects, indicate in
plan$ctFile and plan$contoursFile the path to their file, previously saved to disk (in DEK
format). Or mixed situations.
Radiation fields definition: Fields (field) of the radiation treatment are set by defining
a specific data.frame. Different field correspond to different data.frame rows. Each field
is caracterise by a beamline model, by a pair of angles (gantry and patient table), the
target volume, from the interspot spacing, an isocenter and an external edge of the target
volume coverage.
We want to irradiate the patient with two orthogonal proton fields lying onthe axial plane.
The target is the PTV, and we want to cover it with an external 10 mm margin. The
margin extension helps to get a more uniform dose coverage in the target volume, at the
expense of a small increase in dose around this volume, the healthy part of the patient.
It’s possible to create the fields requested through the command:
fields <- create.field(beamline = ’protonSimple’, targetVOI = ’PTV’, iecGantryAngle =
c(90, 180), spotsExtensionOutsideTarget = 10)
The create.field parameters are optional. Where they are not used, they have been left
to default values.
The fields object is then "hooked" in the plan:
plan$fields <- fields
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Defining the method of calculation: In this section, we specify the quantities that
it’s possible to calculate with the simulation, the resolution of the calculation grid and
any cut-off.
If we want to calculate the physical dose, and the RBE of a computing grid of voxel
dimensions 5× 5× 5 mm, it is necessary to modify the object plan as follows:
plan$computingValues <- c( ’Dose [Gy]’, ’RBE’)
plan$computingGridVoxelSizes <- c(5, 5, 5)
It’s possible to define the region volume where you want to calculate the dose and other
variables. This region can be a portion of the total volume of the CT. For example, to
calculate the dose only in ’BODY’:
plan$computingGridCoverageVOI <- ’BODY’
To speed up the calculations (and save memory, mandatory if you are working on remote
server) it is possible to define a geometrical radius of the cut-off beyond which the single
pencil-beam does not contribute to the total dose. By default, this radius is set to 100
mm. To make a quick sample calculation as example we set the radius to 20 mm:
plan$cutOffRadius <- 20
Alternatively, you can define an effective radius, through the percentage of the total
energy released outside this range to neglect, using the field plan$cutEnergyFraction.
Forward planning
In order to calculate a forward planning, the complete definition of beams must be present
in plan. While in the inverse-planning the radiation information is taken from plan$fields,
in the case of forward planning this information is taken from plan$beams. This field
is automatically filled when you run the inverse-planning with run.dek.inverse. If you
create a plan from scratch, it is still possible to load an object beams with beams <-
read.beams( ’file.beams’) (DEK format) and "hook" to plan with plan$beams <- Beams,
or alternatively directly with plan$inputBeamsFile <- ’file.beams’.
Then we perform forward planning:
plan.out <- read.plan(’plan-example’)
plan.forw.out <- run.dek.forward(plan.out)
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It’s finally posible to assess the contribution of each field. We have already in the object
beams the total radiation information, just then split beams in the components depending
on the gantry angle.
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Create DVHs
We have developed some useful MATLAB scripts for analyzing the biological dose. The
goal is to create the DVHs, the most effective way for analyzing the dose distribution.
The work flux counts basically 3 steps:
• Convert the DEKGPU dose file to plankit values.3d file
• If VOIs are not present, create the VOIs file
• Compute DVHs
We can convert the DEKGPU dose file to plankit values.3d file thanks to the function
convertDEKGPU2values(valueFilExample,DEKGPUfilename,outfile).
This funtion has as input:
• filename of an example values.3d with the coordinate definition (the dose values are
not needed).
• file name of the DEKGPU 3D dose
• the name of the out file
and as output:
• file with the dose in DEK values.3d format.
To work in MATLAB we have to load correctly the DEK values with the function load-
Values(fileName, wantFigure).
This function has as input
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• "*.value.3d"
and as output:
• variable type struct x, y, z, xTag,yTag,zTag,valuesNames,values(Ndoses,x,y,z)
We can create VOIs with the function createVOIs(contourfileName, valuesFilename, cre-
ateFile, VOIsfileName).
This function has as input
• filename of "*.contours.3d"
• file name of "*values.3d" to use as reference for 3D matrix
• if you want to save the file: "y" or "n"
• the name of the file VOIsfileName
and as output:
• booleam cell of {Nvois, x× y × z}
Then it’s possible to load the VOIs with loadVOIs(fileName).
This function has as input
• filename of the vois.3d file
and as output:
• variable type struct x, y, z, xTag, yTag, zTag, voiNames, isInVOI(VOI,x,y,z)
Finally, it’s possible to compute the DVHs with computeDVH(voisFileName, valuesFile-
Name).
This function has as input
• filename of the vois.3d file
• filename of the values.3d file
and as output:
• cell arrays
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